<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2609222641
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2022
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Rivax
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        RIVAROXABAN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        2.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        101
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        190.20
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Hetero Labs Limited Unit &#x2013; V" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Hetero Labs Limited Unit – V
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Rivax contains the active substance rivaroxaban and is used in adults to:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; prevent blood clots in brain (stroke) and other blood vessels in your body if you have a form of irregular heart rhythm called non-valvular atrial fibrillation.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; treat blood clots in the veins of your legs (deep vein thrombosis) and in the blood vessels of your lungs (pulmonary embolism), and to prevent blood clots from re-occurring in the blood vessels of your legs and/or lungs.</p><p>Rivax belongs to a group of medicines called antithrombotic agents. It works by blocking a blood clotting factor (factor Xa) and thus reducing the tendency of the blood to form clots.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Rivax</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to rivaroxaban or any of the other ingredients of this medicine (listed in section 6)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are bleeding excessively</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a disease or condition in an organ of the body that increases the risk of serious bleeding (e.g. stomach ulcer, injury or bleeding in the brain, recent surgery of the brain or eyes)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking medicines to prevent blood clotting (e.g. warfarin, dabigatran, apixaban or heparin), except when changing anticoagulant treatment or while getting heparin through a venous or arterial line to keep it open.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a liver disease which leads to an increased risk of bleeding</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are pregnant or breast-feeding</p><p><strong>Do not take Rivax and tell your doctor </strong>if any of these apply to you.</p><p>Warnings and precautions</p><p>Talk to your doctor or pharmacist before taking Rivax.</p><p>Take special care with Rivax</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have an increased risk of bleeding, as could be the case in situations such as:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe kidney disease, since your kidney function may affect the amount of medicine that works in your body</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking other medicines to prevent blood clotting (e.g. warfarin, dabigatran, apixaban or heparin), when changing anticoagulant treatment or while getting heparin through a venous or arterial line to keep it open (see section &ldquo;Other medicines and Rivax&rdquo;)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding disorders</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; very high blood pressure, not controlled by medical treatment</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diseases of your stomach or bowel that might result in bleeding, e.g. inflammation of the bowels or stomach, or inflammation of the oesophagus (gullet), e.g. due to gastroesophageal reflux disease (disease where stomach acid goes upwards into the oesophagus)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a problem with the blood vessels in the back of your eyes (retinopathy)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a lung disease where your bronchi are widened and filled with pus (bronchiectasis), or previous bleeding from your lung</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a prosthetic heart valve</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you know that you have a disease called antiphospholipid syndrome (a disorder of the immune system that causes an increased risk of blood clots), tell your doctor who will decide if the treatment may need to be changed.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if your doctor determines that your blood pressure is unstable or another treatment or surgical procedure to remove the blood clot from your lungs is planned</p><p>&nbsp;</p><p><strong>If any of the above apply to you, tell your doctor </strong>before you take Rivax. Your doctor will decide, if you should be treated with this medicine and if you should be kept under closer observation.</p><p>If you need to have an operation</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; it is very important to take Rivax before and after the operation exactly at the times you have been told by your doctor.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your operation involves a catheter or injection into your spinal column (e.g. for epidural or spinal anaesthesia or pain reduction):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; it is very important to take Rivax before and after the injection or removal of the catheter exactly at the times you have been told by your doctor</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tell your doctor immediately if you get numbness or weakness of your legs or problems with your bowel or bladder after the end of anaesthesia, because urgent care is necessary.</p><p>&nbsp;</p><p>Children and adolescents</p><p>Rivax is <strong>not recommended for people under 18 years of age. </strong>There is not enough information on its use in children and adolescents.</p><p>Other medicines and Rivax</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are taking</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some medicines for fungal infections (e.g. fluconazole, itraconazole, voriconazole, posaconazole), unless they are only applied to the skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ketoconazole tablets (used to treat Cushing&rsquo;s syndrome - when the body produces an excess of cortisol)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some medicines for bacterial infections (e.g. clarithromycin, erythromycin)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some anti-viral medicines for HIV / AIDS (e.g. ritonavir)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other medicines to reduce blood clotting (e.g. enoxaparin, clopidogrel or vitamin K antagonists such as warfarin and acenocoumarol)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anti-inflammatory and pain relieving medicines (e.g. naproxen or acetylsalicylic acid)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dronedarone, a medicine to treat abnormal heart beat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some medicines to treat depression (selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs))</p><p><strong>If any of the above apply to you, tell your doctor </strong>before taking Rivax, because the effect of Rivax may be increased. Your doctor will decide, if you should be treated with this medicine and if you should be kept under closer observation.</p><p>If your doctor thinks that you are at increased risk of developing stomach or bowel ulcers, he may also use a preventative ulcer treatment.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are taking</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some medicines for treatment of epilepsy (phenytoin, carbamazepine, phenobarbital)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; St John&rsquo;s Wort (<em>Hypericum perforatum</em>), a herbal product used for depression</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rifampicin, an antibiotic</p><p><strong>If any of the above apply to you, tell your doctor </strong>before taking Rivax, because the effect of Rivax may be reduced. Your doctor will decide, if you should be treated with Rivax and if you should be kept under closer observation.</p><p>Pregnancy and breast-feeding</p><p>Do not take Rivax if you are pregnant or breast-feeding. If there is a chance that you could become pregnant, use a reliable contraceptive while you are taking Rivax. If you become pregnant while you are taking this medicine, tell your doctor immediately, who will decide how you should be treated.</p><p>Driving and using machines</p><p>Rivax may cause dizziness (common side effect) or fainting (uncommon side effect) (see section 4,&rdquo; Possible side effects&rdquo;). You should not drive or use machines if you are affected by these symptoms.</p><p>Rivax contains lactose and sodium</p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p><p>This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &ldquo;sodium-free&rdquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>You must take Rivax together with a meal. Swallow the tablet(s) preferably with water.</p><p>If you have difficulty swallowing the tablet whole, talk to your doctor about other ways to take Rivax. The tablet may be crushed and mixed with water or apple puree immediately before you take it. This mixture should be immediately followed by food.</p><p>If necessary, your doctor may also give you the crushed Rivax tablet through a stomach tube.</p><p>How much to take</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To prevent blood clots in brain (stroke) and other blood vessels in your body The recommended dose is one tablet Rivax 20 mg once a day.</p><p>If you have kidney problems, the dose may be reduced to one tablet Rivax 15 mg once a day.</p><p>If you need a procedure to treat blocked blood vessels in your heart (called a percutaneous coronary intervention - PCI with an insertion of a stent), there is limited evidence to reduce the dose to one tablet Rivax 15 mg once a day (or to one tablet Rivax 10 mg once a day in case your kidneys are not working properly) in addition to an antiplatelet medicinal product such as clopidogrel.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To treat blood clots in the veins of your legs and blood clots in the blood vessels of your lungs, and for preventing blood clots from re-occurring</p><p>The recommended dose is one tablet Rivax 15 mg twice a day for the first 3 weeks. For treatment after 3 weeks, the recommended dose is one tablet Rivax 20 mg once a day.</p><p>After at least 6 months&rsquo; blood clot treatment your doctor may decide to continue treatment with either one 10 mg tablet once a day or one 20 mg tablet once a day.</p><p>If you have kidney problems and take one tablet Rivax 20 mg once a day, your doctor may decide to reduce the dose for the treatment after 3 weeks to one tablet Rivax 15 mg once a day if the risk for bleeding is greater than the risk for having another blood clot.</p><p>When to take Rivax</p><p>Take the tablet(s) every day until your doctor tells you to stop.</p><p>Try to take the tablet(s) at the same time every day to help you to remember it. Your doctor will decide how long you must continue treatment.</p><p>To prevent blood clots in the brain (stroke) and other blood vessels in your body:</p><p>If your heart beat needs to be restored to normal by a procedure called cardioversion, take Rivax at the times your doctor tells you.</p><p>If you take more Rivax than you should</p><p>Contact your doctor immediately if you have taken too many Rivax tablets. Taking too much Rivax increases the risk of bleeding.</p><p>If you forget to take Rivax</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are taking one 20 mg tablet or one 15 mg tablet once a day and have missed a dose, take it as soon as you remember. Do not take more than one tablet in a single day to make up for a forgotten dose. Take the next tablet on the following day and then carry on taking one tablet once a day.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are taking one 15 mg tablet twice a day and have missed a dose, take it as soon as you remember. Do not take more than two 15 mg tablets in a single day. If you forget to take a dose you can take two 15 mg tablets at the same time to get a total of two tablets (30 mg) on one day. On the following day you should carry on taking one 15 mg tablet twice a day.</p><p>If you stop taking Rivax</p><p>Do not stop taking Rivax without talking to your doctor first, because Rivax treats and prevents serious conditions.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Like other similar medicines (antithrombotic agents), Rivax may cause bleeding which may potentially be life threatening. Excessive bleeding may lead to a sudden drop in blood pressure (shock). In some cases the bleeding may not be obvious.</p><p>Possible side effects which may be a sign of bleeding</p><p><strong>Tell your doctor immediately i</strong>f you experience any of the following side effects:</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->long or excessive bleeding</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->exceptional weakness, tiredness, paleness, dizziness, headache, unexplained swelling, breathlessness, chest pain or angina pectoris, which may be signs of bleeding.</p><p>Your doctor may decide to keep you under closer observation or change how you should be treated.</p><p><strong>Possible side effects which may be a sign of severe skin reaction Tell your doctor immediately </strong>if you experience skin reactions such as:</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->spreading intense skin rash, blisters or mucosal lesions, e.g. in the mouth or eyes (Stevens-Johnson syndrome/toxic epidermal necrolysis). The frequency of this side effect is very rare (up to 1 in 10,000).</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->a drug reaction that causes rash, fever, inflammation of internal organs, hematologic abnormalities and systemic illness (DRESS syndrome). The frequency of this side effect is very rare (up to 1 in 10,000).</p><p>Possible side effects which may be a sign of severe allergic reactions</p><p><strong>Tell your doctor immediately </strong>if you experience any of the following side effects:</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->swelling of the face, lips, mouth, tongue or throat; difficulty swallowing; hives and breathing difficulties; sudden drop in blood pressure. The frequencies of these side effects are very rare (anaphylactic reactions, including anaphylactic shock; may affect up to 1 in 10,000 people) and uncommon (angioedema and allergic oedema; may affect up to 1 in 100 people).</p><p><strong>Overall list of possible side effects Common </strong>(may affect up to 1 in 10 people)</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->reduction in red blood cells which can make the skin pale and cause weakness or breathlessness</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->bleeding in the stomach or bowel, urogenital bleeding (including blood in the urine and heavy menstrual bleeding), nose bleed, bleeding in the gum</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->bleeding into the eye (including bleeding from the whites of the eyes)</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->bleeding into tissue or a cavity of the body (haematoma, bruising)</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->coughing up blood</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->bleeding from the skin or under the skin</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->bleeding following an operation</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->oozing of blood or fluid from surgical wound</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->swelling in the limbs</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->pain in the limbs</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->impaired function of the kidneys (may be seen in tests performed by your doctor)</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->fever</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->stomach ache, indigestion, feeling or being sick, constipation, diarrhoea</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->low blood pressure (symptoms may be feeling dizzy or fainting when standing up)</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->decreased general strength and energy (weakness, tiredness), headache, dizziness</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->rash, itchy skin</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->blood tests may show an increase in some liver enzymes</p><p>&nbsp;</p><p><strong>Uncommon </strong>(may affect up to 1 in 100 people)</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->bleeding into the brain or inside the skull</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->bleeding into a joint causing pain and swelling</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->thrombocytopenia (low number of platelets, which are cells that help blood to clot)</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->allergic reactions, including allergic skin reactions</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->impaired function of the liver (may be seen in tests performed by your doctor)</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->blood tests may show an increase in bilirubin, some pancreatic or liver enzymes or in the number of platelets</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->fainting</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->feeling unwell</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->faster heartbeat</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->dry mouth</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->hives</p><p><strong>Rare </strong>(may affect up to 1 in 1,000 people)</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->bleeding into a muscle</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->cholestasis (decreased bile flow), hepatitis incl. hepatocellular injury (inflamed liver incl. liver injury)</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->yellowing of the skin and eye (jaundice)</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->localised swelling</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->collection of blood (haematoma) in the groin as a complication of the cardiac procedure where a catheter is inserted in your leg artery (pseudoaneurysm)</p><p><strong>Not known </strong>(frequency cannot be estimated from the available data)</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->kidney failure after a severe bleeding</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->increased pressure within muscles of the legs or arms after a bleeding, which leads to pain, swelling, altered sensation, numbness or paralysis (compartment syndrome after a bleeding)</p><p>&nbsp;</p><p>Reporting of side effects</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects, you can help provide more information on the safety of this medicine.</p><p><!--[if !supportLists]-->&bull;&nbsp; <!--[endif]-->Saudi Arabia<em>:</em></p><p>The National Pharmacovigilance and Drug Safety Centre (NPC) o SFDA Call Center: 19999</p><p>o&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>o&nbsp; Website:https://ade.sfda.gov.sa/</p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><strong><em>o Other GCC States:</em></strong></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep out of the reach and sight of children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date stated on the blister and carton. The expiry date refers to the last day of that month.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store below 30&ordm;C.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store in the original package in order to protect from moisture.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp;&nbsp; What Rivax contains:</p><p><strong><u>Rivax (Rivaroxaban 2.5 mg):</u></strong></p><p>Each film coated tablet contains Rivaroxaban 2.5mg.</p><p><strong>The other ingredients are: </strong>Cellulose, microcrystalline (Grade 101), Lactose monohydrate (Grade 200M), Croscarmellose sodium, Hypromellose 2910,5cps, Sodiumlauril sulfate, Magnesium stearate, Purified water, Opadry white, Opadry 04F530020 Orange, Opadry 04F57002 Grey and Opadry 04F57000 Grey</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Rivax (Rivaroxaban 2.5 mg):
White to off-white, film coated, round shaped biconvex tablets, debossed with “R20” on one side and “H” on the other side.
How supplied:
2.5 mg: 6×10’s Blister pack. 


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Saudi Amarox Industrial Company</p><p>Aljameah Street, Malaz quarter, Riyadh 11441 Saudi Arabia</p><p>Tel: +966 11 477 2215</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                07/2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي ريفاكس على المادة الفعالة ريفاروكسابان ويستخدم للبالغين من أجل:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;منع الجلطات الدموية في الدماغ (السكتة الدماغية) والأوعية الدموية الأخرى في جسمك إذا كان لديك شكل من أشكال عدم انتظام ضربات القلب يسمى الرجفان الأذيني غير الصمامي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;يعالج الجلطات الدموية في أوردة الساق (تجلط الأوردة العميقة) وفي الأوعية الدموية في رئتيك (الانسداد الرئوي) ، ولمنع تكرار حدوث الجلطات الدموية في الأوعية الدموية في ساقيك و / أو رئتيك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينتمي ريفاكس إلى مجموعة من الأدوية تسمى العوامل المضادة للتخثر. وهو يعمل عن طريق منع عامل تخثر الدم (العامل إكس أ) وبالتالي تقليل ميل الدم لتكوين الجلطات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول ريفاكس</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا كنت تعاني من حساسية تجاه عقار ريفاروكسابان أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم 6)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا كنت تنزف بغزارة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا كنت تعاني من مرض أو حالة في أحد أعضاء الجسم تزيد من خطر حدوث نزيف خطير (مثل قرحة في المعدة ، أو إصابة أو نزيف في الدماغ ، أو جراحة حديثة للمخ أو العين)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا كنت تتناول أدوية لمنع تخثر الدم (مثل وارفارين أو دابيجاتران أو أبيكسابان أو هيبارين) ، إلا عند تغيير العلاج المضاد للتخثر أو أثناء الحصول على الهيبارين عبر خط وريدي أو شرياني لإبقائه مفتوحًا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا كان لديك مرض كبدي يؤدي إلى زيادة خطر النزيف</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا كنت حاملا أو مرضعة</p><p dir="RTL"><strong>لا تتناول ريفاكس</strong><strong> </strong><strong>وأخبر طبيبك إذا كان أي منها ينطبق عليك</strong>.</p><p dir="RTL"><strong>التحذيرات والإحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي قبل تناول ريفاكس.</p><p dir="RTL"><strong>انتبه بشكل خاص مع تناول ريفاكس</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا كان لديك خطر متزايد من النزيف ، كما هو الحال في حالات مثل:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمراض الكلى الحادة ، حيث أن وظائف الكلى لديك قد تؤثر على كمية الأدوية التي تعمل في جسمك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أدوية أخرى لمنع تخثر الدم (على سبيل المثال ، وارفارين ، دابيجاتران ، أبيكسابان أو هيبارين) ، عند تغيير العلاج المضاد للتخثر أو أثناء إدخال الهيبارين عبر خط وريدي أو شرياني لإبقائه مفتوحًا (انظر قسم &quot;الأدوية الأخرى و ريفاكس&quot;)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات النزيف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع شديد في ضغط الدم لا يتحكم فيه العلاج الطبي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمراض المعدة أو الأمعاء التي قد تؤدي إلى النزيف ، على سبيل المثال التهاب الأمعاء أو المعدة ، أو التهاب المريء ، على سبيل المثال. بسبب مرض الارتجاع المعدي المريئي (المرض الذي يرتفع فيه حمض المعدة إلى المريء)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلة في الأوعية الدموية في مؤخرة العين (اعتلال الشبكية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض الرئة حيث تتسع القصبات الهوائية وتمتلئ بالصديد (توسع القصبات) ، أو نزيف سابق من رئتيك</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا كان لديك صمام قلب اصطناعي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا كنت تعلم أنك تعاني من مرض يسمى متلازمة مضادات الشحوم الفوسفورية (اضطراب في الجهاز المناعي يؤدي إلى زيادة خطر الإصابة بجلطات الدم) ، أخبر طبيبك الذي سيقرر ما إذا كان العلاج بحاجة إلى تغيير.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا قرر طبيبك أن ضغط دمك غير مستقر أو إذا تم التخطيط لعلاج آخر أو إجراء جراحي لإزالة الجلطة الدموية من رئتيك</p><p dir="RTL"><strong>إذا انطبق عليك أي مما سبق، أخبر طبيبك</strong> قبل أن تتناول ريفاكس. سيقرر طبيبك ما إذا كان يجب أن تعالج بهذا الدواء وما إذا كان يجب أن تبقى تحت المراقبة الدقيقة.</p><p dir="RTL"><strong>إذا كنت بحاجة إلى إجراء عملية جراحية</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>&nbsp;</strong>من المهم جدًا تناول ريفاكس قبل العملية وبعدها بالضبط في الأوقات التي أخبرك بها طبيبك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا تضمنت عمليتك قسطرة أو حقنًا في العمود الفقري (على سبيل المثال للتخدير فوق الجافية أو التخدير النخاعي أو تقليل الألم):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من المهم جدًا تناول ريفاكس قبل وبعد الحقن أو إزالة القسطرة بالضبط في الأوقات التي أخبرك بها طبيبك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبر طبيبك على الفور إذا شعرت بخدر أو ضعف في ساقيك أو مشاكل في الأمعاء أو المثانة بعد انتهاء التخدير ، لأن الرعاية العاجلة ضرورية.</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL"><strong>لا ينصح باستخدام ريفاكس</strong><strong> </strong><strong>للأشخاص الذين تقل أعمارهم عن 18 عامًا</strong>. لا توجد معلومات كافية عن استخدامه في الأطفال والمراهقين.</p><p dir="RTL"><strong>تناول الأدوية الأخرى و ريفاكس</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى ، بما في ذلك الأدوية التي تم الحصول عليها بدون وصفة طبية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا كنت تتناول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية للعدوى الفطرية (مثل فلوكونازول ، إيتراكونازول ، فوريكونازول ، بوساكونازول) ، ما لم يتم وضعها على الجلد فقط</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أقراص الكيتوكونازول (تُستخدم لعلاج متلازمة كوشينغ عندما ينتج الجسم فائضًا من الكورتيزول)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية للعدوى البكتيرية (مثل كلاريثروميسين وإريثروميسين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية المضادة للفيروسات لفيروس نقص المناعة البشرية / الإيدز (مثل ريتونافير)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية الأخرى لتقليل تخثر الدم (مثل إينوكسابارين أو كلوبيدوجريل أو مضادات فيتامين ك مثل الوارفارين وأسينوكومارول)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المضادة للالتهابات وتسكين الآلام (مثل نابروكسين أو حمض أسيتيل الساليسيليك)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; درونيدارون ، دواء لعلاج ضربات القلب غير الطبيعية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية لعلاج الاكتئاب (مثبطات امتصاص السيروتونين الانتقائية (SSRIs) أو مثبطات امتصاص السيروتونين (SNRIs)(</p><p dir="RTL"><strong>إذا انطبق عليك أي مما سبق، أخبر طبيبك</strong> قبل تناول ريفاكس ، لأن تأثير ريفاكس قد يزداد. سيقرر طبيبك ما إذا كان يجب أن تعالج بهذا الدواء وما إذا كان يجب أن تبقى تحت المراقبة الدقيقة.</p><p dir="RTL">إذا اعتقد طبيبك أنك في خطر متزايد للإصابة بقرحة في المعدة أو الأمعاء، فقد يستخدم أيضًا علاجًا وقائيًا للقرحة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;<strong>إذا كنت تتناول</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية لعلاج الصرع (الفينيتوين ، كاربامازيبين ، الفينوباربيتال)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبتة سانت جون (Hypericum perfratum) ، منتج عشبي يستخدم لعلاج الاكتئاب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفامبيسين ، مضاد حيوي</p><p dir="RTL"><strong>إذا انطبق عليك أي مما سبق ، أخبر طبيبك</strong> قبل تناول ريفاكس ، لأن تأثير ريفاكس قد ينخفض. سيقرر طبيبك ما إذا كان يجب أن تعالج ب ريفاكس وما إذا كان يجب أن تبقى تحت المراقبة الدقيقة.</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">لا تتناولي ريفاكس إذا كنت حاملا أو مرضعة. إذا كانت هناك فرصة للحمل، فاستخدمي وسيلة موثوقة لمنع الحمل أثناء تناول ريفاكس. إذا أصبحت حاملاً أثناء تناول هذا الدواء، أخبر طبيبك على الفور، والذي سيقرر كيفية علاجك.</p><p dir="RTL"><strong>القيادة واستعمال الآلات</strong></p><p dir="RTL">قد يسبب ريفاكس دوار (عرض جانبي شائع) أو إغماء (أثر جانبي غير شائع) (انظر القسم 4 ، &quot;الآثار الجانبية المحتملة&quot;). يجب ألا تقود السيارة أو تستخدم الآلات إذا كنت تعاني من هذه الأعراض.</p><p dir="RTL"><strong>يحتوي ريفاكس</strong><strong> </strong><strong>على اللاكتوز والصوديوم</strong></p><p dir="RTL">إذا أخبرك طبيبك أنك لديك مشكلة من تحمل بعض السكريات، فاتصل بطبيبك قبل تناول هذا الدواء.</p><p dir="RTL">يحتوي هذا الدواء على أقل من 1 مليمول صوديوم (23 ملغم ) لكل قرص، وهذا يعني بشكل أساسي &quot;خالٍ من الصوديوم&quot;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احرص دائمًا على تناول هذا الدواء تمامًا كما أخبرك طبيبك. استشر طبيبك أو الصيدلي إذا لم تكن متأكدًا.</p><p dir="RTL">يجب أن تتناول ريفاكس مع الوجبة.</p><p dir="RTL">يفضل ابتلاع القرص (الأقراص) بالماء.</p><p dir="RTL">إذا كنت تواجه صعوبة في ابتلاع القرص بالكامل ، فتحدث إلى طبيبك حول طرق أخرى لتناول ريفاكس. يمكن سحق القرص وخلطه بالماء أو هريس التفاح قبل تناوله مباشرة. يجب أن يتبع هذا الخليط مباشرة بالطعام.</p><p dir="RTL">إذا لزم الأمر، قد يعطيك طبيبك أيضًا قرص ريفاكس المسحوق من خلال أنبوب المعدة.</p><p dir="RTL"><strong>الجرعة</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;لمنع تجلط الدم في الدماغ (السكتة الدماغية) والأوعية الدموية الأخرى في جسمك</p><p dir="RTL">الجرعة الموصى بها هي قرص واحد من ريفاكس 20 ملغم مرة واحدة في اليوم.</p><p dir="RTL">إذا كنت تعاني من مشاكل في الكلى، يمكن تقليل الجرعة إلى قرص واحد من ريفاكس 15 ملغم مرة واحدة في اليوم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت بحاجة إلى إجراء لعلاج انسداد الأوعية الدموية في قلبك (يسمى التدخل التاجي عن طريق الجلد PCI بإدخال دعامة)، فهناك أدلة محدودة لتقليل الجرعة إلى قرص واحد من ريفاكس 15 ملغم مرة واحدة في اليوم (أو إلى قرص واحد) قرص ريفاكس 10 ملغم مرة واحدة في اليوم في حالة عدم عمل الكليتين بشكل صحيح) بالإضافة إلى منتج طبي مضاد للصفيحات مثل كلوبيدوجريل.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;لعلاج الجلطات الدموية في أوردة الساقين وجلطات الدم في الأوعية الدموية في رئتيك ، ولمنع حدوث جلطات الدم مرة أخرى</p><p dir="RTL">الجرعة الموصى بها هي قرص واحد من ريفاكس 15 ملغم مرتين في اليوم خلال الأسابيع الثلاثة الأولى. للعلاج بعد 3 أسابيع، الجرعة الموصى بها هي قرص واحد من ريفاكس 20 ملغم مرة واحدة في اليوم.</p><p dir="RTL">بعد علاج جلطة الدم لمدة 6 أشهر على الأقل، قد يقرر طبيبك مواصلة العلاج إما باستخدام قرص واحد 10 ملغم مرة واحدة في اليوم أو قرص واحد 20 ملغم مرة واحدة في اليوم.</p><p dir="RTL">إذا كنت تعاني من مشاكل في الكلى وتناول قرصًا واحدًا من ريفاكس 20 ملغم مرة واحدة يوميًا ، فقد يقرر طبيبك تقليل جرعة العلاج بعد 3 أسابيع إلى قرص واحد ريفاكس 15 ملغم مرة واحدة يوميًا إذا كان خطر النزيف أكبر من خطر الإصابة وجود جلطة دموية أخرى.</p><p dir="RTL"><strong>موعد تناول جرعة ريفاكس اقراص</strong></p><p dir="RTL">تناول القرص (الأقراص) كل يوم حتى يخبرك طبيبك بالتوقف.</p><p dir="RTL">حاول أن تتناول القرص (الأقراص) في نفس الوقت كل يوم لمساعدتك على تذكرها.</p><p dir="RTL">سيقرر طبيبك كم من الوقت يجب أن تستمر في العلاج.</p><p dir="RTL"><strong>لمنع تجلط الدم في الدماغ (السكتة الدماغية) والأوعية الدموية الأخرى في جسمك</strong><strong>:</strong></p><p dir="RTL">إذا كانت ضربات قلبك بحاجة إلى العودة إلى طبيعتها من خلال إجراء يسمى تقويم نظم القلب، فتناول ريفاكس في الأوقات التي يخبرك طبيبك بها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول جرعة زائدة من ريفاكس أقراص</strong></p><p dir="RTL">اتصل بطبيبك على الفور إذا كنت قد تناولت الكثير من أقراص ريفاكس. إن تناول الكثير من ريفاكس يزيد من خطر حدوث نزيف.</p><p dir="RTL"><strong>إذا نسيت تناول ريفاكس</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا كنت تتناول قرصًا واحدًا 20 ملغم أو قرصًا واحدًا تركيز 15 ملغم مرة واحدة يوميًا وفقدت جرعة ، فتناولها بمجرد أن تتذكرها. لا تتناول أكثر من قرص واحد في يوم واحد لتعويض الجرعة المنسية. تناول القرص التالي في اليوم التالي ثم استمر في تناول قرص واحد مرة واحدة في اليوم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا كنت تتناول قرصًا واحدًا تركيز 15 ملغم مرتين في اليوم وفقدت جرعة ، فتناولها حالما تتذكرها. لا تتناول أكثر من قرصين 15 ملغم في يوم واحد. إذا نسيت تناول جرعة، يمكنك تناول قرصين 15 ملغم في نفس الوقت للحصول على إجمالي قرصين (30 مجم) في يوم واحد. في اليوم التالي يجب أن تستمر في تناول قرص واحد تركيز 15 ملغم مرتين في اليوم.</p><p dir="RTL"><strong>التوقفت عن تناول ريفاكس أقراص</strong></p><p dir="RTL">لا تتوقف عن تناول ريفاكس دون التحدث إلى طبيبك أولاً، لأن ريفاكس يعالج الحالات الخطيرة ويمنعها.</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، على الرغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">مثل الأدوية الأخرى المماثلة (العوامل المضادة للتخثرات)، قد يتسبب ريفاكس في حدوث نزيف قد يكون مهددًا للحياة. قد يؤدي النزيف المفرط إلى انخفاض مفاجئ في ضغط الدم (صدمة). في بعض الحالات، قد لا يكون النزيف واضحًا.</p><p dir="RTL"><strong>الأعراض الجانبية التي قد تكون علامة على حدوث نزيف</strong></p><p dir="RTL"><strong>أخبر طبيبك على الفور</strong> إذا واجهت أيًا من الآثار الجانبية التالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;نزيف لفترة طويلة أو مفرط</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;ضعف استثنائي ، إرهاق ، شحوب ، دوار ، صداع ، إنتفاخ غير مبرر ، ضيق تنفس ، ألم في الصدر أو ذبحة صدرية ، والتي قد تكون علامات نزيف.</p><p dir="RTL">قد يقرر طبيبك أن يبقيك تحت المراقبة عن كثب أو يغير طريقة علاجك.</p><p dir="RTL"><strong>الآثار الجانبية المحتملة التي قد تكون علامة على تفاعل شديد في الجلد</strong></p><p dir="RTL"><strong>أخبر طبيبك على الفور</strong> إذا كنت تعاني من ردود فعل جلدية مثل:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;انتشار طفح جلدي شديد أو بثور أو آفات مخاطية ، على سبيل المثال. في الفم أو العينين (متلازمة ستيفنز جونسون / انحلال البشرة السمي النخري). حيث أن معدل هذا العرض الجانبي نادر جدًا (يصل إلى 1 في 10000).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;تفاعل دوائي يسبب طفح جلدي وحمى والتهاب في الأعضاء الداخلية وتشوهات دموية وأمراض جهازية (متلازمة دريس). حيث أن معدل هذا العرض الجانبي نادر جدًا (يصل إلى 1 في 10000).</p><p dir="RTL"><strong>الآثار الجانبية المحتملة التي قد تكون علامة على ردود فعل تحسسية شديدة</strong></p><p dir="RTL"><strong>أخبر طبيبك على الفور</strong> إذا واجهت أيًا من الآثار الجانبية التالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;انتفاخ الوجه ، الشفتين ، الفم ، اللسان أو الحلق. صعوبة في البلع تورمات وصعوبات في التنفس. انخفاض مفاجئ في ضغط الدم. حيث أن معدل هذه الآثار الجانبية نادر جدًا (تفاعلات تأقية ، بما في ذلك صدمة الحساسية ؛ قد تؤثر على ما يصل إلى 1 من كل 10000 شخص) وغير شائعة (ورم وعائية وورم تحسسي ؛ قد تؤثر على حتى 1 من كل 100 شخص).</p><p dir="RTL"><strong>قائمة شاملة من الآثار الجانبية المحتملة</strong></p><p dir="RTL"><strong>شائعة </strong>(قد تظهر لدى مايصل إلى شخص من كل 10 أشخاص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;انخفاض في خلايا الدم الحمراء مما قد يجعل الجلد شاحبًا ويسبب ضعفًا أو ضيقًا في التنفس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;نزيف في المعدة أو الأمعاء ، نزيف في الجهاز البولي التناسلي (بما في ذلك دم في البول ونزيف حاد في الدورة الشهرية) ، نزيف من الأنف ، نزيف في اللثة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;نزيف في العين (بما في ذلك نزيف من بياض العين).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;نزيف في الأنسجة أو تجويف الجسم (ورم دموي ، كدمات)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السعال الدموي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;نزيف من الجلد أو تحت الجلد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;نزيف بعد العملية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;نزف دم أو سوائل من الجرح الجراحي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;انتفاخ في الاطراف</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;ألم في الأطراف</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;خلل في وظائف الكلى (يمكن رؤيته في الاختبارات التي يقوم بها طبيبك)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;آلام في المعدة ، عسر هضم ، شعور أو مرض ، إمساك ، إسهال</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;انخفاض ضغط الدم (قد تكون الأعراض هي الشعور بالدوار أو الإغماء عند الوقوف).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;قلة القوة العامة والطاقة (ضعف ، إرهاق) ، صداع ، دوار</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;طفح جلدي وحكة في الجلد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;قد تظهر فحوصات الدم زيادة في بعض أنزيمات الكبد</p><p dir="RTL"><strong>غير شائعة</strong> (قد تظهر لدى مايصل إلى شخص من كل 100 شخص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;نزيف في المخ أو داخل الجمجمة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;نزيف في المفصل يسبب الألم والتورم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;قلة الصفيحات (انخفاض عدد الصفائح الدموية ، وهي خلايا تساعد الدم على التجلط)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;ردود الفعل التحسسية بما في ذلك تفاعلات حساسية الجلد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;خلل في وظائف الكبد (يمكن رؤيته في الاختبارات التي يجريها طبيبك)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;قد تظهر فحوصات الدم زيادة في البيليروبين وبعض إنزيمات البنكرياس أو الكبد أو في عدد الصفائح الدموية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إغماء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;الشعور بتوعك</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;سرعة ضربات القلب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فم جاف</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL"><strong>نادرة</strong> (قد تظهر لدى حتى 1 من كل 1000 شخص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;نزيف في العضل</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;ركود صفراوي (انخفاض تدفق الصفراء) ، التهاب الكبد. إصابة خلايا الكبد (التهاب الكبد بما في ذلك إصابة الكبد)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;اصفرار الجلد والعين (اليرقان)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;انتفاخ موضعي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;تجمع الدم (ورم دموي) في الفخذ كمضاعفات لعملية القلب حيث يتم إدخال قسطرة في شريان الساق (تمدد الأوعية الدموية الكاذب)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير معروف</strong> (لا يمكن تقدير معدلاتها من البيانات المتاحة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;فشل كلوي بعد نزيف حاد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;زيادة الضغط داخل عضلات الساقين أو الذراعين بعد حدوث نزيف ، مما يؤدي إلى الألم أو التورم أو تغير الإحساس أو التنميل أو الشلل (متلازمة الحيّز بعد النزيف)</p><p><strong>الإبلاغ عن الآثار الجانبية: </strong></p><p>إذا زادت حدة أي من هذه الأعراض الجانبية، أو لاحظت ظهور أعراض جانبية غير ما تم ذكره في هذه النشرة، يرجى إبلاغ الطبيب المعالج أو الصيدلي. وهذا يشمل أي آثار جانبية محتملة غير مدرجة في هذه النشرة. يمكنك أيضا الإبلاغ عن الآثار الجانبية مباشرة (انظر التفاصيل أدناه). بالإبلاغ عن الآثار الجانبية يمكنك المساعدة في توفير مزيد من المعلومات حول أمان هذا الدواء.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكة العربية السعودية</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المركز الوطني للتيقظ والسلامة الدوائية</strong></p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; مركز الاتصال بالهيئة العامة للغذاء والدواء: 19999</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://ade.sfda.gov.sa/</p><p><strong>دول مجلس التعاون الخليجي الأخرى:</strong></p><p>يرجى الاتصال بالسلطة الصحية المختصة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ بعيدا عن متناول وبصر الأطفال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة والكرتون. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من نفس الشهر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ في درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب التخزين في العلبة الأصلية لحمايته من الرطوبة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا ينبغي التخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. إسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبة. ومن شأن هذه التدابير أن تساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ماذا يحتوي ريفاكس</strong><strong>:</strong></p><p dir="RTL"><strong>ريفاكس</strong><strong> </strong><strong>(ريفاروكسابان</strong><strong> </strong><strong>2.5 ملغم ) </strong><strong>:</strong></p><p dir="RTL">كل قرص مغلف يحتوي على ريفاروكسابان 2.5 ملغم .<strong> </strong></p><p dir="RTL"><strong>المكونات الأخرى هي:</strong></p><p dir="RTL">السليلوز</p><p dir="RTL">الجريزوفولفين (درجة 101)</p><p dir="RTL">اللاكتوز أحادي الهيدرات (درجة 200 م)</p><p dir="RTL">&nbsp;الصوديوم كروس كارميلوز</p><p dir="RTL">هيبروميلوز 2910 ،5CPS</p><p dir="RTL">كبريتات لوريل الصوديوم</p><p dir="RTL">ستيرات الماغنيسيوم</p><p dir="RTL">المياه النقية</p><p dir="RTL">أوبادري 04F530020</p><p dir="RTL">برتقالي ، أوبادري 04F57002</p><p dir="RTL">رمادي وأوبادري 04F57000</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كيف تبدو ريفاكس أقراص؟</strong></p><p dir="RTL"><strong>ريفاكس</strong><strong> </strong><strong>(ريفاروكسابان</strong><strong> </strong><strong>2.5 ملغم ) </strong><strong>:</strong></p><p dir="RTL">أقراص بيضاء إلى بيضاء مائلة للصفرة ، مغطاة بطبقة رقيقة ، مستديرة محدبة الوجهين ، مدموغ عليها حرف &quot;R20&quot; على جانب واحد و &quot;H&quot; على الجانب الآخر.</p><p dir="RTL"><strong>كيف تتوفر</strong><strong>:</strong></p><p dir="RTL">يتم توفير ريفاكس (أقراص ريفاروكسابان) في</p><p dir="RTL">2.5 ملغم: شرائط 6 &times; 10.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>شركة أماروكس السعودية للصناعة</strong></p><p>شارع الجامعة &ndash; الملز &ndash; الرياض 11441</p><p>المملكة العربية السعودية.</p><p>تليفون: + 966 114772215</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            12/2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Rivaroxaban Tablets 2.5mg
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film coated tablet contains Rivaroxaban 2.5mg 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Rivaroxaban Tablets 2.5 mg: 
White to off-white, film coated, round shaped biconvex tablets, debossed with “R20” on one side and “H” on the other side. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age &ge; 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.&nbsp;Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology&nbsp;</u></p><p><em>Prevention of stroke and systemic embolism </em>&nbsp;</p><p>The recommended dose is 20 mg once daily, which is also the recommended maximum dose.&nbsp;</p><p>Therapy with Xarelto should be continued long term provided the benefit of prevention of stroke and systemic embolism outweighs the risk of bleeding (see section 4.4).&nbsp;</p><p>If a dose is missed the patient should take Xarelto immediately and continue on the following day with the once daily intake as recommended. The dose should not be doubled within the same day to make up for a missed dose.&nbsp;</p><p><em>Treatment of DVT, treatment of PE and prevention of recurrent DVT and PE</em>&nbsp;</p><p>The recommended dose for the initial treatment of acute DVT or PE is 15 mg twice daily for the first three weeks followed by 20 mg once daily for the continued treatment and prevention of recurrent DVT and PE.&nbsp;</p><p>Short duration of therapy (at least 3 months) should be considered in patients with DVT or PE provoked by major transient risk factors (i.e. recent major surgery or trauma). Longer duration of therapy should be considered in patients with provoked DVT or PE not related to major transient risk factors, unprovoked DVT or PE, or a history of recurrent DVT or PE.&nbsp;</p><p>When extended prevention of recurrent DVT and PE is indicated (following completion of at least 6 months&rsquo; therapy for DVT or PE), the recommended dose is 10 mg once daily. In patients in whom the risk of recurrent DVT or PE is considered high, such as those with complicated comorbidities, or who have developed recurrent DVT or PE on extended prevention with Xarelto 10 mg once daily, a dose of Xarelto 20 mg once daily should be considered.</p><p>The duration of therapy and dose selection should be individualised after careful assessment of the treatment benefit against the risk for bleeding (see section 4.4).&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p><strong>Time period</strong>&nbsp;</p></td><td><p><strong>Dosing schedule</strong>&nbsp;</p></td><td><p><strong>Total daily dose</strong>&nbsp;</p></td></tr><tr><td rowspan="2"><p>Treatment and prevention of recurrent</p><p>DVT and PE</p></td><td><p>Day 1 - 21</p></td><td><p>15 mg twice daily&nbsp;</p></td><td><p>30 mg</p></td></tr><tr><td><p>Day 22 onwards</p></td><td><p>20 mg once daily&nbsp;</p></td><td><p>20 mg</p></td></tr><tr><td><p>Prevention of recurrent</p><p>DVT and PE&nbsp;</p></td><td><p>Following completion of at least 6 months</p></td><td><p>10 mg once daily or 20 mg once daily&nbsp;</p></td><td><p>10 mg or 20 mg</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>therapy for DVT or PE</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>To support the dose switch from 15 mg to 20 mg after Day 21 a first 4 weeks treatment initiation pack of Xarelto for treatment of DVT/PE is available.</p><p>If a dose is missed during the 15 mg twice daily treatment phase (day 1 - 21), the patient should take Xarelto immediately to ensure intake of 30 mg Xarelto per day. In this case two 15 mg tablets may be taken at once. The patient should continue with the regular 15 mg twice daily intake as recommended on the following day.&nbsp;</p><p>If a dose is missed during the once daily treatment phase, the patient should take Xarelto immediately, and continue on the following day with the once daily intake as recommended. The dose should not be doubled within the same day to make up for a missed dose.&nbsp;</p><p><em>Converting from Vitamin K Antagonists (VKA) to Xarelto</em>&nbsp;</p><p>For patients treated for prevention of stroke and systemic embolism, VKA treatment should be stopped and Xarelto therapy should be initiated when the International Normalised Ratio (INR) is &le; 3.0. &nbsp;</p><p>For patients treated for DVT, PE and prevention of recurrence, VKA treatment should be stopped and Xarelto therapy should be initiated once the INR is &le; 2.5. &nbsp;</p><p>When converting patients from VKAs to Xarelto, INR values will be falsely elevated after the intake of Xarelto. The INR is not valid to measure the anticoagulant activity of Xarelto, and therefore should not be used (see section 4.5).</p><p><em>Converting from Xarelto to Vitamin K antagonists (VKA)</em>&nbsp;</p><p>There is a potential for inadequate anticoagulation during the transition from Xarelto to VKA. Continuous adequate anticoagulation should be ensured during any transition to an alternate anticoagulant. It should be noted that Xarelto can contribute to an elevated INR.&nbsp;</p><p>In patients converting from Xarelto to VKA, VKA should be given concurrently until the INR is &ge; 2.0. For the first two days of the conversion period, standard initial dosing of VKA should be used followed by VKA dosing, as guided by INR testing. While patients are on both Xarelto and VKA the INR should not be tested earlier than 24 hours after the previous dose but prior to the next dose of Xarelto. Once Xarelto is discontinued INR testing may be done reliably at least 24 hours after the last dose (see sections 4.5 and 5.2).</p><p><em>Converting from parenteral anticoagulants to Xarelto</em>&nbsp;</p><p>For patients currently receiving a parenteral anticoagulant, discontinue the parenteral anticoagulant and start Xarelto 0 to 2 hours before the time that the next scheduled administration of the parenteral medicinal product (e.g. low molecular weight heparins) would be due or at the time of discontinuation of a continuously administered parenteral medicinal product (e.g. intravenous unfractionated heparin).</p><p><em>Converting from Xarelto to parenteral anticoagulants</em>&nbsp;</p><p>Give the first dose of parenteral anticoagulant at the time the next Xarelto dose would be taken.&nbsp;</p><p><u>Special populations&nbsp;</u></p><p><em>Renal impairment</em>&nbsp;</p><p>Limited clinical data for patients with severe renal impairment (creatinine clearance 15 - 29 ml/min) indicate that rivaroxaban plasma concentrations are significantly increased. Therefore, Xarelto is to be used with caution in these patients. Use is not recommended in patients with creatinine clearance &lt; 15 ml/min (see sections 4.4 and 5.2).</p><p>In patients with moderate (creatinine clearance 30 - 49 ml/min) or severe (creatinine clearance 15 - 29 ml/min) renal impairment the following dose recommendations apply:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, the recommended dose is 15 mg once daily (see section 5.2).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For the treatment of DVT, treatment of PE and prevention of recurrent DVT and PE: patients should be treated with 15 mg twice daily for the first 3 weeks. Thereafter, when the recommended dose is 20 mg once daily, a reduction of the dose from 20 mg once daily to 15 mg once daily should be considered if the patient&#39;s assessed risk for bleeding outweighs the risk for recurrent DVT and PE. The recommendation for the use of 15 mg is based on PK modelling and has not been studied in this clinical setting (see sections 4.4, 5.1 and 5.2).&nbsp;</p><p>When the recommended dose is 10 mg once daily, no dose adjustment from the recommended dose is necessary.&nbsp;</p><p>No dose adjustment is necessary in patients with mild renal impairment (creatinine clearance 50 - 80 ml/min) (see section 5.2).&nbsp;</p><p><em>Hepatic impairment</em>&nbsp;</p><p>Xarelto is contraindicated in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk including cirrhotic patients with Child Pugh B and C (see sections 4.3 and 5.2).</p><p><em>Elderly population </em>&nbsp;</p><p>No dose adjustment (see section 5.2)</p><p><em>Body weight</em>&nbsp;</p><p>No dose adjustment (see section 5.2)</p><p><em>Gender</em>&nbsp;</p><p>No dose adjustment (see section 5.2)</p><p><em>Paediatric population</em>&nbsp;</p><p>The safety and efficacy of Xarelto in children aged 0 to 18 years have not been established. No data are available. Therefore, Xarelto is not recommended for use in children below 18 years of age.&nbsp;</p><p><em>Patients undergoing cardioversion</em>&nbsp;</p><p>Xarelto can be initiated or continued in patients who may require cardioversion.&nbsp;</p><p>For transesophageal echocardiogram (TEE) guided cardioversion in patients not previously treated with anticoagulants, Xarelto treatment should be started at least 4 hours before cardioversion to ensure adequate anticoagulation (see sections 5.1 and 5.2). For all patients, confirmation should be sought prior to cardioversion that the patient has taken Xarelto as prescribed. Decisions on initiation and duration of treatment should take established guideline recommendations for anticoagulant treatment in patients undergoing cardioversion into account.</p><p><em>Patients with non-valvular atrial fibrillation who undergo PCI (percutaneous coronary intervention) with stent placement</em>&nbsp;</p><p>There is limited experience of a reduced dose of 15 mg Xarelto once daily (or 10 mg Xarelto once daily for patients with moderate renal impairment [creatinine clearance 30 - 49 ml/min]) in addition to a P2Y12 inhibitor for a maximum of 12 months in patients with non-valvular atrial fibrillation who require oral anticoagulation and undergo PCI with stent placement (see sections</p><p>4.4 and 5.1).&nbsp;</p><p><u>Method of administration&nbsp;</u></p><p>Xarelto is for oral use.&nbsp;</p><p>The tablets are to be taken with food (see section 5.2).</p><p>For patients who are unable to swallow whole tablets, Xarelto tablet may be crushed and mixed with water or apple puree immediately prior to use and administered orally. After the administration of crushed Xarelto 15 mg or 20 mg film-coated tablets, the dose should be immediately followed by food.</p><p>The crushed Xarelto tablet may also be given through gastric tubes after confirmation of the correct gastric placement of the tube. The crushed tablet should be administered in a small amount of water via a gastric tube after which it should be flushed with water. After the administration of crushed Xarelto 15 mg or 20 mg film-coated tablets, the dose should then be immediately followed by enteral feeding (see section 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Active clinically significant bleeding.

Lesion or condition, if considered to be a significant risk for major bleeding. This may include current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities.

Concomitant treatment with any other anticoagulants, e.g. unfractionated heparin (UFH), low molecular weight heparins (enoxaparin, dalteparin, etc.), heparin derivatives (fondaparinux, etc.), oral anticoagulants (warfarin, dabigatran etexilate, apixaban, etc.) except under specific circumstances of switching anticoagulant therapy (see section 4.2) or when UFH is given at doses necessary to maintain an open central venous or arterial catheter (see section 4.5).

Hepatic disease associated with coagulopathy and clinically relevant bleeding risk including cirrhotic patients with Child Pugh B and C (see section 5.2).

Pregnancy and breast-feeding (see section 4.6).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clinical surveillance in line with anticoagulation practice is recommended throughout the treatment period.</p><p><u>Haemorrhagic risk&nbsp;</u></p><p>As with other anticoagulants, patients taking Xarelto are to be carefully observed for signs of bleeding. It is recommended to be used with caution in conditions with increased risk of haemorrhage. Xarelto administration should be discontinued if severe haemorrhage occurs (see section 4.9).</p><p>In the clinical studies mucosal bleedings (i.e. epistaxis, gingival, gastrointestinal, genito urinary including abnormal vaginal or increased menstrual bleeding) and anaemia were seen more frequently during long term rivaroxaban treatment compared with VKA treatment. Thus, in addition to adequate clinical surveillance, laboratory testing of haemoglobin/haematocrit could be of value to detect occult bleeding and quantify the clinical relevance of overt bleeding, as judged to be appropriate.</p><p>Several sub-groups of patients, as detailed below, are at increased risk of bleeding. These patients are to be carefully monitored for signs and symptoms of bleeding complications and anaemia after initiation of treatment (see section 4.8).&nbsp;</p><p>Any unexplained fall in haemoglobin or blood pressure should lead to a search for a bleeding site.</p><p>Although treatment with rivaroxaban does not require routine monitoring of exposure, rivaroxaban levels measured with a calibrated quantitative anti-factor Xa assay may be useful in exceptional situations where knowledge of rivaroxaban exposure may help to inform clinical decisions, e.g. overdose and emergency surgery (see sections 5.1 and 5.2).</p><p><u>Renal impairment&nbsp;</u></p><p>In patients with severe renal impairment (creatinine clearance &lt; 30 ml/min) rivaroxaban plasma levels may be significantly increased (1.6 fold on average) which may lead to an increased bleeding risk. Xarelto is to be used with caution in patients with creatinine clearance 15 - 29 ml/min. Use is not recommended in patients with creatinine clearance &lt; 15 ml/min (see sections</p><p>4.2 and 5.2).</p><p>Xarelto should be used with caution in patients with renal impairment concomitantly receiving other medicinal products which increase rivaroxaban plasma concentrations (see section 4.5).</p><p><u>Interaction with other medicinal products&nbsp;</u></p><p>The use of Xarelto is not recommended in patients receiving concomitant systemic treatment with azole-antimycotics (such as ketoconazole, itraconazole, voriconazole and posaconazole) or HIV protease inhibitors (e.g. ritonavir). These active substances are strong inhibitors of both CYP3A4 and P-gp and therefore may increase rivaroxaban plasma concentrations to a clinically relevant degree (2.6 fold on average) which may lead to an increased bleeding risk (see section 4.5).</p><p>Care is to be taken if patients are treated concomitantly with medicinal products affecting haemostasis such as non-steroidal anti-inflammatory medicinal products (NSAIDs), acetylsalicylic acid and platelet aggregation inhibitors or selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs). For patients at risk of ulcerative gastrointestinal disease an appropriate prophylactic treatment may be considered (see section 4.5).&nbsp;</p><p><u>Other haemorrhagic risk factors&nbsp;</u></p><p>As with other antithrombotics, rivaroxaban is not recommended in patients with an increased bleeding risk such as:</p><p>&bull;&nbsp; congenital or acquired bleeding disorders</p><p>&bull;&nbsp; uncontrolled severe arterial hypertension</p><p>&bull;&nbsp; other gastrointestinal disease without active ulceration that can potentially lead to bleeding complications (e.g. inflammatory bowel disease, oesophagitis, gastritis and gastroesophageal reflux disease)</p><p>&bull;&nbsp; vascular retinopathy</p><p>&bull;&nbsp; bronchiectasis or history of pulmonary bleeding</p><p><u>Patients with prosthetic valves&nbsp;</u></p><p>Rivaroxaban should not be used for thromboprophylaxis in patients having recently undergone transcatheter aortic valve replacement (TAVR). Safety and efficacy of Xarelto have not been studied in patients with prosthetic heart valves; therefore, there are no data to support that Xarelto provides adequate anticoagulation in this patient population. Treatment with Xarelto is not recommended for these patients.</p><p><u>Patients with antiphospholipid syndrome&nbsp;</u></p><p>Direct acting Oral Anticoagulants (DOACs) including rivaroxaban are not recommended for patients with a history of thrombosis who are diagnosed with antiphospholipid syndrome. In particular for patients that are triple positive (for lupus anticoagulant, anticardiolipin antibodies, and anti-beta 2-glycoprotein I antibodies), treatment with DOACs could be associated with increased rates of recurrent thrombotic events compared with vitamin K antagonist therapy.</p><p><u>Patients with non-valvular atrial fibrillation who undergo PCI with stent placement&nbsp;</u></p><p>Clinical data are available from an interventional study with the primary objective to assess safety in patients with non-valvular atrial fibrillation who undergo PCI with stent placement. Data on efficacy in this population are limited (see sections 4.2 and 5.1). No data are available for such patients with a history of stroke/TIA.</p><p><u>Haemodynamically unstable PE patients or patients who require thrombolysis or pulmonary embolectomy&nbsp;</u></p><p>Xarelto is not recommended as an alternative to unfractionated heparin in patients with pulmonary embolism who are haemodynamically unstable or may receive thrombolysis or pulmonary embolectomy since the safety and efficacy of Xarelto have not been established in these clinical situations.&nbsp;</p><p><u>Spinal/epidural anaesthesia or puncture&nbsp;</u></p><p>When neuraxial anaesthesia (spinal/epidural anaesthesia) or spinal/epidural puncture is employed, patients treated with antithrombotic agents for prevention of thromboembolic complications are at risk of developing an epidural or spinal haematoma which can result in long-term or permanent paralysis. The risk of these events may be increased by the postoperative use of indwelling epidural catheters or the concomitant use of medicinal products affecting haemostasis. The risk may also be increased by traumatic or repeated epidural or spinal puncture. Patients are to be frequently monitored for signs and symptoms of neurological impairment (e.g. numbness or weakness of the legs, bowel or bladder dysfunction). If neurological compromise is noted, urgent diagnosis and treatment is necessary. Prior to neuraxial intervention the physician should consider the potential benefit versus the risk in anticoagulated patients or in patients to be anticoagulated for thromboprophylaxis. There is no clinical experience with the use of 20 mg rivaroxaban in these situations.&nbsp;</p><p>To reduce the potential risk of bleeding associated with the concurrent use of rivaroxaban and neuraxial (epidural/spinal) anaesthesia or spinal puncture, consider the pharmacokinetic profile of rivaroxaban. Placement or removal of an epidural catheter or lumbar puncture is best performed when the anticoagulant effect of rivaroxaban is estimated to be low. However, the exact timing to reach a sufficiently low anticoagulant effect in each patient is not known.</p><p>For the removal of an epidural catheter and based on the general PK characteristics at least 2x half-life, i.e. at least 18 hours in young patients and 26 hours in elderly patients should elapse after the last administration of rivaroxaban (see section 5.2). Following removal of the catheter, at least 6 hours should elapse before the next rivaroxaban dose is administered.</p><p>If traumatic puncture occurs the administration of rivaroxaban is to be delayed for 24 hours.</p><p><u>Dosing recommendations before and after invasive procedures and surgical intervention&nbsp;</u></p><p>If an invasive procedure or surgical intervention is required, Xarelto 20 mg should be stopped at least 24 hours before the intervention, if possible and based on the clinical judgement of the physician.&nbsp;</p><p>If the procedure cannot be delayed the increased risk of bleeding should be assessed against the urgency of the intervention.</p><p>Xarelto should be restarted as soon as possible after the invasive procedure or surgical intervention provided the clinical situation allows and adequate haemostasis has been established as determined by the treating physician (see section 5.2).</p><p><u>Elderly population</u>&nbsp;</p><p>Increasing age may increase haemorrhagic risk (see section 5.2).</p><p><u>Dermatological reactions&nbsp;</u></p><p>Serious skin reactions, including Stevens-Johnson syndrome/toxic epidermal necrolysis and DRESS syndrome, have been reported during post-marketing surveillance in association with the use of rivaroxaban (see section 4.8). Patients appear to be at highest risk for these reactions early in the course of therapy: the onset of the reaction occurring in the majority of cases within the first weeks of treatment. Rivaroxaban should be discontinued at the first appearance of a severe skin rash (e.g. spreading, intense and/or blistering), or any other sign of hypersensitivity in conjunction with mucosal lesions.</p><p>Information about excipients&nbsp;</p><p>Xarelto contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>CYP3A4 and P-gp inhibitors&nbsp;</u></p><p>Co-administration of rivaroxaban with ketoconazole (400 mg once a day) or ritonavir (600 mg twice a day) led to a 2.6 fold / 2.5 fold increase in mean rivaroxaban AUC and a 1.7 fold / 1.6 fold increase in mean rivaroxaban C<sub>max</sub>, with significant increases in pharmacodynamic effects which may lead to an increased bleeding risk. Therefore, the use of Xarelto is not recommended in patients receiving concomitant systemic treatment with azole-antimycotics such as ketoconazole, itraconazole, voriconazole and posaconazole or HIV protease inhibitors. These active substances are strong inhibitors of both CYP3A4 and P-gp (see section 4.4).&nbsp;</p><p>Active substances strongly inhibiting only one of the rivaroxaban elimination pathways, either</p><p>CYP3A4 or P-gp, are expected to increase rivaroxaban plasma concentrations to a lesser extent. Clarithromycin (500 mg twice a day), for instance, considered as a strong CYP3A4 inhibitor and moderate P-gp inhibitor, led to a 1.5 fold increase in mean rivaroxaban AUC and a 1.4 fold increase in C<sub>max</sub>. The interaction with clarithromycin is likely not clinically relevant in most patients but can be potentially significant in high-risk patients. (For patients with renal impairment: see section 4.4).</p><p>Erythromycin (500 mg three times a day), which inhibits CYP3A4 and P-gp moderately, led to a 1.3 fold increase in mean rivaroxaban AUC and C<sub>max</sub>. The interaction with erythromycin is likely not clinically relevant in most patients but can be potentially significant in high-risk patients.</p><p>In subjects with mild renal impairment erythromycin (500 mg three times a day) led to a 1.8 fold increase in mean rivaroxaban AUC and 1.6 fold increase in C<sub>max</sub> when compared to subjects with normal renal function. In subjects with moderate renal impairment, erythromycin led to a 2.0 fold increase in mean rivaroxaban AUC and 1.6 fold increase in C<sub>max</sub> when compared to subjects with normal renal function. The effect of erythromycin is additive to that of renal impairment (see section 4.4).</p><p>Fluconazole (400 mg once daily), considered as a moderate CYP3A4 inhibitor, led to a 1.4 fold increase in mean rivaroxaban AUC and a 1.3 fold increase in mean C<sub>max</sub>. The interaction with fluconazole is likely not clinically relevant in most patients but can be potentially significant in high-risk patients. (For patients with renal impairment: see section 4.4).</p><p>Given the limited clinical data available with dronedarone, co-administration with rivaroxaban should be avoided.</p><p><u>Anticoagulants&nbsp;</u></p><p>After combined administration of enoxaparin (40 mg single dose) with rivaroxaban (10 mg single dose) an additive effect on anti-factor Xa activity was observed without any additional effects on clotting tests (PT, aPTT). Enoxaparin did not affect the pharmacokinetics of rivaroxaban.</p><p>Due to the increased bleeding risk care is to be taken if patients are treated concomitantly with any other anticoagulants (see sections 4.3 and 4.4).&nbsp;</p><p><u>NSAIDs/platelet aggregation inhibitors&nbsp;</u></p><p>No clinically relevant prolongation of bleeding time was observed after concomitant administration of rivaroxaban (15 mg) and 500 mg naproxen. Nevertheless, there may be individuals with a more pronounced pharmacodynamic response.&nbsp;</p><p>No clinically significant pharmacokinetic or pharmacodynamic interactions were observed when rivaroxaban was co-administered with 500 mg acetylsalicylic acid.</p><p>Clopidogrel (300 mg loading dose followed by 75 mg maintenance dose) did not show a pharmacokinetic interaction with rivaroxaban (15 mg) but a relevant increase in bleeding time was observed in a subset of patients which was not correlated to platelet aggregation, P-selectin or GPIIb/IIIa receptor levels.</p><p>Care is to be taken if patients are treated concomitantly with NSAIDs (including acetylsalicylic acid) and platelet aggregation inhibitors because these medicinal products typically increase the bleeding risk (see section 4.4).</p><p><u>SSRIs/SNRIs&nbsp;</u></p><p>As with other anticoagulants the possibility may exist that patients are at increased risk of bleeding in case of concomitant use with SSRIs or SNRIs due to their reported effect on platelets. When concomitantly used in the rivaroxaban clinical programme, numerically higher rates of major or non-major clinically relevant bleeding were observed in all treatment groups.</p><p><u>Warfarin&nbsp;</u></p><p>Converting patients from the vitamin K antagonist warfarin (INR 2.0 to 3.0) to rivaroxaban (20 mg) or from rivaroxaban (20 mg) to warfarin (INR 2.0 to 3.0) increased prothrombin time/INR (Neoplastin) more than additively (individual INR values up to 12 may be observed), whereas effects on aPTT, inhibition of factor Xa activity and endogenous thrombin potential were additive.&nbsp;</p><p>If it is desired to test the pharmacodynamic effects of rivaroxaban during the conversion period, anti-factor Xa activity, PiCT, and Heptest can be used as these tests were not affected by warfarin. On the fourth day after the last dose of warfarin, all tests (including PT, aPTT, inhibition of factor Xa activity and ETP) reflected only the effect of rivaroxaban.&nbsp;</p><p>If it is desired to test the pharmacodynamic effects of warfarin during the conversion period, INR measurement can be used at the C<sub>trough</sub> of rivaroxaban (24 hours after the previous intake of rivaroxaban) as this test is minimally affected by rivaroxaban at this time point.</p><p>No pharmacokinetic interaction was observed between warfarin and rivaroxaban.</p><p><u>CYP3A4 inducers&nbsp;</u></p><p>Co-administration of rivaroxaban with the strong CYP3A4 inducer rifampicin led to an approximate 50% decrease in mean rivaroxaban AUC, with parallel decreases in its pharmacodynamic effects. The concomitant use of rivaroxaban with other strong CYP3A4 inducers (e.g. phenytoin, carbamazepine, phenobarbital or St. John&#39;s Wort <em>(Hypericum perforatum)</em>) may also lead to reduced rivaroxaban plasma concentrations. Therefore, concomitant administration of strong CYP3A4 inducers should be avoided unless the patient is closely observed for signs and symptoms of thrombosis.</p><p><u>Other concomitant therapies&nbsp;</u></p><p>No clinically significant pharmacokinetic or pharmacodynamic interactions were observed when rivaroxaban was co-administered with midazolam (substrate of CYP3A4), digoxin (substrate of P-gp), atorvastatin (substrate of CYP3A4 and P-gp) or omeprazole (proton pump inhibitor). Rivaroxaban neither inhibits nor induces any major CYP isoforms like CYP3A4.</p><p><u>Laboratory parameters&nbsp;</u></p><p>Clotting parameters (e.g. PT, aPTT, HepTest) are affected as expected by the mode of action of rivaroxaban (see section 5.1).&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy&nbsp;</u></p><p>Safety and efficacy of Xarelto have not been established in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). Due to the potential reproductive toxicity, the intrinsic risk of bleeding and the evidence that rivaroxaban passes the placenta, Xarelto is contraindicated during pregnancy (see section 4.3).&nbsp;</p><p>Women of child-bearing potential should avoid becoming pregnant during treatment with rivaroxaban.</p><p><u>Breast-feeding&nbsp;</u></p><p>Safety and efficacy of Xarelto have not been established in breast-feeding women. Data from animals indicate that rivaroxaban is secreted into milk. Therefore Xarelto is contraindicated during breast-feeding (see section 4.3). A decision must be made whether to discontinue breastfeeding or to discontinue/abstain from therapy.&nbsp;</p><p><u>Fertility&nbsp;</u></p><p>No specific studies with rivaroxaban in humans have been conducted to evaluate effects on fertility. In a study on male and female fertility in rats no effects were seen (see section 5.3).&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Xarelto has minor influence on the ability to drive and use machines. Adverse reactions like syncope (frequency: uncommon) and dizziness (frequency: common) have been reported (see section 4.8). Patients experiencing these adverse reactions should not drive or use machines</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile&nbsp;</u></p><p>The safety of rivaroxaban has been evaluated in thirteen phase III studies including 53,103 patients exposed to rivaroxaban (see Table 1).</p><p><strong>Table 1: Number of patients studied, total daily dose and maximum treatment duration in phase III studies</strong>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Indication</strong>&nbsp;</p></td><td><p><strong>Number of patients*</strong>&nbsp;</p></td><td><p><strong>Total daily dose</strong>&nbsp;</p></td><td><p><strong>Maximum treatment duration</strong>&nbsp;</p></td></tr><tr><td><p>Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or</p><p>knee replacement surgery</p></td><td><p>6,097</p></td><td><p>10 mg</p></td><td><p>39 days</p></td></tr><tr><td><p>Prevention of VTE in medically ill patients</p></td><td><p>3,997</p></td><td><p>10 mg</p></td><td><p>39 days</p></td></tr><tr><td><p>Treatment of DVT, PE and prevention of recurrence</p></td><td><p>6,790</p></td><td><p>Day 1 - 21: 30 mg Day 22 and onwards: 20 mg</p><p>After at least 6 months: 10 mg or 20 mg</p></td><td><p>21 months</p></td></tr><tr><td><p>Prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation</p></td><td><p>7,750</p></td><td><p>20 mg</p></td><td><p>41 months</p></td></tr><tr><td><p>Prevention of atherothrombotic events in patients after an acute coronary syndrome (ACS)</p></td><td><p>10,225</p></td><td><p>5 mg or 10 mg respectively, coadministered with either ASA or ASA plus clopidogrel or ticlopidine</p></td><td><p>31 months</p></td></tr><tr><td><p>Prevention of atherothrombotic events in patients with CAD/PAD</p></td><td><p>18,244</p></td><td><p>5 mg coadministered with ASA or 10 mg alone</p></td><td><p>47 months</p></td></tr><tr><td colspan="4"><p>* Patients exposed to at least one dose of rivaroxaban</p></td></tr></tbody></table><p>The most commonly reported adverse reactions in patients receiving rivaroxaban were bleedings (see section 4.4. and &#39;Description of selected adverse reactions&#39; below) (Table 2). The most commonly reported bleedings were epistaxis (4.5 %) and gastrointestinal tract haemorrhage (3.8 %).</p><p><strong>Table 2: Bleeding* and anaemia events rates in patients exposed to rivaroxaban across the completed phase III studies</strong>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Indication</strong>&nbsp;</p></td><td><p><strong>Any bleeding</strong>&nbsp;</p></td><td><p><strong>Anaemia</strong>&nbsp;</p></td></tr><tr><td><p>Prevention of VTE in adult patients undergoing elective hip or knee replacement surgery</p></td><td><p>6.8% of patients</p></td><td><p>5.9% of patients</p></td></tr><tr><td><p>Prevention of VTE in medically ill patients</p></td><td><p>12.6% of patients</p></td><td><p>2.1% of patients</p></td></tr><tr><td><p>Treatment of DVT, PE and prevention of recurrence</p></td><td><p>23% of patients</p></td><td><p>1.6% of patients</p></td></tr><tr><td><p>Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation</p></td><td><p>28 per 100 patient years</p></td><td><p>2.5 per 100 patient years</p></td></tr><tr><td><p>Prevention of atherothrombotic events in patients after an ACS</p></td><td><p>22 per 100 patient years</p></td><td><p>1.4 per 100 patient years</p></td></tr><tr><td><p>Prevention of atherothrombotic events in patients with CAD/PAD</p></td><td><p>6.7 per 100 patient years</p></td><td><p>0.15 per 100 patient years**&nbsp;</p></td></tr><tr><td colspan="3"><p>* For all rivaroxaban studies all bleeding events are collected, reported and adjudicated.&nbsp; ** In the COMPASS study, there is a low anaemia incidence as a selective approach to adverse event collection was applied</p></td></tr></tbody></table><p><u>Tabulated list of adverse reactions&nbsp;</u></p><p>The frequencies of adverse reactions reported with Xarelto are summarised in Table 3 below by system organ class (in MedDRA) and by frequency.&nbsp;</p><p>Frequencies are defined as: very common (&ge; 1/10) common (&ge; 1/100 to &lt; 1/10) &nbsp;uncommon (&ge; 1/1,000 to &lt; 1/100) &nbsp;rare (&ge; 1/10,000 to &lt; 1/1,000) very rare ( &lt; 1/10,000) not known (cannot be estimated from the available data)</p><p><strong>Table 3: All adverse reactions reported in patients in phase III clinical trials or through post-marketing use*&nbsp; </strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Common</strong>&nbsp;</p></td><td><p><strong>Uncommon</strong>&nbsp;</p></td><td><p><strong>Rare</strong>&nbsp;</p></td><td><p><strong>Very rare</strong>&nbsp;</p></td><td><p><strong>Not known</strong>&nbsp;</p></td></tr><tr><td colspan="3"><p><strong>Blood and lymphatic system disorders</strong>&nbsp;</p><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Anaemia (incl.</p><p>respective laboratory</p></td><td><p>Thrombocytosis</p><p>(incl. platelet count increased)<sup>A</sup>,</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>parameters)</p></td><td><p>Thrombocytopenia</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Immune system disorders</strong>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Allergic reaction, dermatitis allergic,</p><p>Angioedema and allergic oedema</p></td><td><p>&nbsp;</p></td><td><p>Anaphylactic reactions including anaphylactic shock&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Nervous system disorders</strong>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p></td></tr><tr><td><p>Dizziness, headache</p></td><td><p>Cerebral and intracranial haemorrhage, syncope</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Eye disorders</strong>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p></td></tr><tr><td><p>Eye haemorrhage (incl. conjunctival haemorrhage)</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Cardiac disorders</strong>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Tachycardia</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Vascular disorders</strong>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p></td></tr><tr><td colspan="5"><p>Hypotension, haematoma</p></td></tr><tr><td colspan="5"><p><strong>Respiratory, thoracic and mediastinal disorders</strong>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p></td></tr><tr><td><p>Epistaxis, haemoptysis</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Gastrointestinal disorders</strong>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p></td></tr><tr><td><p>Gingival bleeding, gastrointestinal tract haemorrhage</p><p>(incl. rectal haemorrhage), gastrointestinal and abdominal pains, dyspepsia, nausea, constipation<sup>A</sup>,</p></td><td><p>Dry mouth</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>diarrhoea, vomiting<sup>A</sup></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Hepatobiliary disorders</strong>&nbsp;</p><p>&nbsp; &nbsp;</p></td></tr><tr><td><p>Increase in transaminases</p></td><td><p>Hepatic impairment, Increased bilirubin, increased blood alkaline phosphatase<sup>A</sup>, increased GGT<sup>A</sup></p></td><td><p>Jaundice, Bilirubin conjugated increased (with or without concomitant increase of ALT),</p><p>Cholestasis, Hepatitis (incl. hepatocellular injury)</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Skin and subcutaneous tissue disorders</strong>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p></td></tr><tr><td colspan="5"><p><!--[if gte vml 1]><v:group id="Group_x0020_54714" o:spid="_x0000_s1047"
   style='position:absolute;left:0;text-align:left;margin-left:93.85pt;
   margin-top:-4.3pt;width:.7pt;height:130pt;z-index:251659264;
   mso-position-horizontal-relative:text;mso-position-vertical-relative:text'
   coordsize="91,16507" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Shape_x0020_64305" o:spid="_x0000_s1048" style='position:absolute;
    width:91;height:198;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="9144,19812" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l9144,r,19812l,19812,,e" fillcolor="#7b7b7b" stroked="f"
    strokeweight="0">
    <v:stroke miterlimit="66585f" joinstyle="miter" endcap="round"/>
    <v:path arrowok="t" textboxrect="0,0,9144,19812"/>
   </v:shape><v:shape id="Shape_x0020_64306" o:spid="_x0000_s1049" style='position:absolute;
    top:198;width:91;height:16309;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="9144,1630934" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQBoQG/nyQAAAN4AAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Ba8JA
FITvgv9heUIvRTetJUh0lba0GFoFjR48PrLPJG32bchuTfrvuwXB4zAz3zCLVW9qcaHWVZYVPEwi
EMS51RUXCo6H9/EMhPPIGmvLpOCXHKyWw8ECE2073tMl84UIEHYJKii9bxIpXV6SQTexDXHwzrY1
6INsC6lb7ALc1PIximJpsOKwUGJDryXl39mPUbBJt032tUvXH2+dvH/hzcl2nyel7kb98xyEp97f
wtd2qhXET9Mohv874QrI5R8AAAD//wMAUEsBAi0AFAAGAAgAAAAhANvh9svuAAAAhQEAABMAAAAA
AAAAAAAAAAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEAWvQsW78AAAAV
AQAACwAAAAAAAAAAAAAAAAAfAQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEAaEBv58kAAADe
AAAADwAAAAAAAAAAAAAAAAAHAgAAZHJzL2Rvd25yZXYueG1sUEsFBgAAAAADAAMAtwAAAP0CAAAA
AA==
" path="m,l9144,r,1630934l,1630934,,e" fillcolor="#7b7b7b" stroked="f"
    strokeweight="0">
    <v:stroke miterlimit="66585f" joinstyle="miter" endcap="round"/>
    <v:path arrowok="t" textboxrect="0,0,9144,1630934"/>
   </v:shape><w:wrap type="square"/>
  </v:group><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_54716"
   o:spid="_x0000_s1044" style='position:absolute;left:0;text-align:left;
   margin-left:188.2pt;margin-top:-4.3pt;width:.7pt;height:130pt;z-index:251660288;
   mso-position-horizontal-relative:text;mso-position-vertical-relative:text'
   coordsize="91,16507" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Shape_x0020_64309" o:spid="_x0000_s1045" style='position:absolute;
    width:91;height:198;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="9144,19812" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l9144,r,19812l,19812,,e" fillcolor="#7b7b7b" stroked="f"
    strokeweight="0">
    <v:stroke miterlimit="66585f" joinstyle="miter" endcap="round"/>
    <v:path arrowok="t" textboxrect="0,0,9144,19812"/>
   </v:shape><v:shape id="Shape_x0020_64310" o:spid="_x0000_s1046" style='position:absolute;
    top:198;width:91;height:16309;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="9144,1630934" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l9144,r,1630934l,1630934,,e" fillcolor="#7b7b7b" stroked="f"
    strokeweight="0">
    <v:stroke miterlimit="66585f" joinstyle="miter" endcap="round"/>
    <v:path arrowok="t" textboxrect="0,0,9144,1630934"/>
   </v:shape><w:wrap type="square"/>
  </v:group><![endif]--><img width="1" height="173" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /><!--[if gte vml 1]><v:group
   id="Group_x0020_54720" o:spid="_x0000_s1041" style='position:absolute;
   left:0;text-align:left;margin-left:282.4pt;margin-top:-4.3pt;width:.7pt;
   height:130pt;z-index:251661312;mso-position-horizontal-relative:text;
   mso-position-vertical-relative:text' coordsize="91,16507" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEApQjQYQ8DAAD9CgAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWzsVltvmzAUfp+0/4B4b4GEkItKq7Xb
+jKtVdP9ANeYgGZsZDsp2a/f8Q1IqnbdJm0PWythY5/zne9cw9lF19BgR4SsOcvD5DQOA8IwL2q2
ycMv9x9PFmEgFWIFopyRPNwTGV6cv31zhlYbgdqqxgEgMLlCeVgp1a6iSOKKNEie8pYwuCu5aJCC
V7GJCoEeAbmh0SSOs6hBNQvPB6j3SKFgK+pfgKIcfyXFFWI7JAGS4tX4xHGk+PeR0YrtrkW7bm+F
Zo4/725FUBd5CJFjqIEQhZG7cGLwGh1pbQaArhSNludlGXR5mM6n08kSsPawn6XxYjGzeKRTAQaB
xULfYrhOslk8zdw1rm5+AICrDy9BAEVLBTYjemar+T3j9SydT3rPrwXftoE9+qtBsPGLXSZ6x5dJ
mg6xm6eZFnjGcdlar58mOkunydQne12hlgT2yLusVXzSvbp09XKU7gOiPsUjmstFMjkgCRW3leqa
cFM0aPdJKmN2U/gdqvwOd8xvBcEqoKZIlXkK83zQT6PfIqX1tM96GzzmoaVRQaEZFvqq4Ttyz42Q
0tU6og9hHG4pG0tZIKhYYwsE/bVfWwPWi1l7NoJexK9W1Np9rdyhWbCvPTSJ772Gw3FcKdMBACsY
tXkoWGGmVFMrIgJaNxCSOMniAdeA+RSrbm1qR3WXvNjrYD3AClMCxqy6gUdJOaBjWrdhUHHx7ejM
5INKtVZ7SmxyNAhhxS0S6A6AKNLTGYmT9TtXHGAQXBgsbiVZt3eQdBtFT0lqSA1G2R0pYWyZHOoD
KTYPVxQ4Il0l5s/4jGhbIXfqbDlRY9HgaP2yprSHTIzqAeT8Uv87BCdsvCpLYNlrxlYTOza2SsFX
SIWvVfCTeCVjmbNBn8GPlKdpfQVx28ovNzTMBTu9h4ZONZCZ8D/d0H1lAlc3dEdNnU3j5dSgAzk/
EMbl94fa2vHQTg6tO24wX+DD7WEb9h3rBf21X48b+8BzL+TXseXk1ZKHpiGg/5v7n2tuyLr7TomO
PvzMkHIfqvrrcvx+/h0AAP//AwBQSwMEFAAGAAgAAAAhAJJ9h+AdBwAASSAAABoAAABjbGlwYm9h
cmQvdGhlbWUvdGhlbWUxLnhtbOxZS28bNxC+F+h/WOy9sWS9YiNyYMly3MQvREqKHCmJ2mXMXS5I
yo5uRXLqpUCBtOihAXrroSgaoAEa9NIfY8BBm/6IDrkvUqLiB1wgKGwBxu7sN8PhzOzM7PDO3WcR
9Y4xF4TFbb96q+J7OB6xMYmDtv9osP3Zbd8TEsVjRFmM2/4MC//uxqef3EHrI0qSIUN8PAhxhD0Q
FIt11PZDKZP1lRUxAjISt1iCY3g2YTxCEm55sDLm6AQWiOjKaqXSXIkQif0NkCiVoB6Ff7EUijCi
vK/EYC9GEax+MJmQEdbY8VFVIcRMdCn3jhFt+yBzzE4G+Jn0PYqEhAdtv6L//JWNOytoPWOicgmv
wbet/zK+jGF8tKrX5MGwWLReb9Sbm4V8DaByEddr9Zq9ZiFPA9BoBDtNdbFltla79QxrgNJLh+yt
1latauEN+bUFnTcb6mfhNSiVX1/Ab293wYoWXoNSfGMB3+isdbZs+RqU4psL+FZlc6vesuRrUEhJ
fLSArjSatW6+2wIyYXTHCV9r1Ldbq5nwEgXRUESXWmLCYrks1iL0lPFtACggRZLEnpwleIJGEJNd
RMmQE2+XBCEEXoJiJoBcWa1sV2rwX/3q+kp7FK1jZHArvUATsUBS+nhixEki2/59kOobkLO3b0+f
vzl9/vvpixenz3/N1taiLL4dFAcm3/ufvvnn1Zfe37/9+P7lt+nS83hh4t/98tW7P/78kHjYcWmK
s+9ev3vz+uz7r//6+aVD+iZHQxM+IBEW3j4+8R6yCDbo0B8P+eU4BiEiJsdmHAgUI7WKQ35PhhZ6
f4YocuA62LbjYw6pxgW8N31qKdwP+VQSh8QHYWQB9xijHcadVnig1jLMPJjGgXtxPjVxDxE6dq3d
RbHl5d40gRxLXCK7IbbUPKQolijAMZaeesaOMHbs7gkhll33yIgzwSbSe0K8DiJOkwzI0IqmkmmH
ROCXmUtB8Ldlm73HXodR16638LGNhHcDUYfyA0wtM95DU4kil8gBiqhp8F0kQ5eS/RkfmbiekODp
AFPm9cZYCBfPAYf9Gk5/AGnG7fY9OotsJJfkyCVzFzFmIrfYUTdEUeLC9kkcmtjPxRGEKPIOmXTB
95j9hqh78AOKl7r7McGWu8/PBo8gw5oqlQGinky5w5f3MLPitz+jE4RdqWaTR1aK3eTEGR2daWCF
9i7GFJ2gMcbeo88dGnRYYtm8VPp+CFllB7sC6z6yY1Xdx1hgTzc3i3lylwgrZPs4YEv02ZvNJZ4Z
iiPEl0neB6+bNu9BqYtcAXBAR0cmcJ9Avwfx4jTKgQAZRnAvlXoYIquAqXvhjtcZt/x3kXcM3sun
lhoXeC+BB1+aBxK7yfNB2wwQtRYoA2aAoMtwpVtgsdxfsqjiqtmmTr6J/dKWboDuyGp6IhKf2wHN
9T6N/673gQ7j7IdXjpftevodt2ArWV2y01mWTHbm+ptluPmupsv4mHz8Tc0WmsaHGOrIYsa66Wlu
ehr/f9/TLHufbzqZZf3GTSfjQ4dx08lkw5Xr6WTK5gX6GjXwSAc9euwTLZ36TAilfTmjeFfowY+A
75nxNhAVn55u4mIKmIRwqcocLGDhAo40j8eZ/ILIsB+iBKZDVV8JCUQmOhBewgQMjTTZKVvh6TTa
Y+N02FmtqsFmWlkFkiW90ijoMKiSKbrZKgd4hXitbaAHrbkCivcyShiL2UrUHEq0cqIykh7rgtEc
SuidXYsWaw4tbivxuasWtADVCq/AB7cHn+ltv1EHFmCCeRw052Plp9TVuXe1M6/T08uMaUUANNh5
BJSeXlO6Lt2e2l0aahfwtKWEEW62EtoyusETIXwGZ9GpqBdR47K+XitdaqmnTKHXg9Aq1Wjd/pAW
V/U18M3nBhqbmYLG3knbb9YaEDIjlLT9CQyN4TJKIHaE+uZCNIDjlpHk6Qt/lcyScCG3kAhTg+uk
k2aDiEjMPUqitq+2X7iBxjqHaN2qq5AQPlrl1iCtfGzKgdNtJ+PJBI+k6XaDoiyd3kKGT3OF86lm
vzpYcbIpuLsfjk+8IZ3yhwhCrNGqKgOOiYCzg2pqzTGBw7AikZXxN1eYsrRrnkbpGErpiCYhyiqK
mcxTuE7lhTr6rrCBcZftGQxqmCQrhMNAFVjTqFY1LapGqsPSqns+k7KckTTLmmllFVU13VnMWiEv
A3O2vFqRN7TKTQw5zazwaeqeT7lrea6b6xOKKgEGL+znqLoXKAiGauVilmpK48U0rHJ2RrVrR77B
c1S7SJEwsn4zFztnt6JGOJcD4pUqP/DNRy2QJnlfqS3tOtjeQ4k3DKptHw6XYTj4DK7geNoH2qqi
rSoaXMGZM5SL9KC47WcXOQWep5QCU8sptRxTzyn1nNLIKY2c0swpTd/TJ6pwiq8OU30vPzCFGpYd
sGa9hX36v/EvAAAA//8DAFBLAwQUAAYACAAAACEAnGZGQbsAAAAkAQAAKgAAAGNsaXBib2FyZC9k
cmF3aW5ncy9fcmVscy9kcmF3aW5nMS54bWwucmVsc4SPzQrCMBCE74LvEPZu0noQkSa9iNCr1AcI
yTYtNj8kUezbG+hFQfCyMLPsN7NN+7IzeWJMk3ccaloBQae8npzhcOsvuyOQlKXTcvYOOSyYoBXb
TXPFWeZylMYpJFIoLnEYcw4nxpIa0cpEfUBXNoOPVuYio2FBqrs0yPZVdWDxkwHii0k6zSF2ugbS
L6Ek/2f7YZgUnr16WHT5RwTLpRcWoIwGMwdKV2edNS1dgYmGff0m3gAAAP//AwBQSwECLQAUAAYA
CAAAACEAu+VIlAUBAAAeAgAAEwAAAAAAAAAAAAAAAAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBL
AQItABQABgAIAAAAIQCtMD/xwQAAADIBAAALAAAAAAAAAAAAAAAAADYBAABfcmVscy8ucmVsc1BL
AQItABQABgAIAAAAIQClCNBhDwMAAP0KAAAfAAAAAAAAAAAAAAAAACACAABjbGlwYm9hcmQvZHJh
d2luZ3MvZHJhd2luZzEueG1sUEsBAi0AFAAGAAgAAAAhAJJ9h+AdBwAASSAAABoAAAAAAAAAAAAA
AAAAbAUAAGNsaXBib2FyZC90aGVtZS90aGVtZTEueG1sUEsBAi0AFAAGAAgAAAAhAJxmRkG7AAAA
JAEAACoAAAAAAAAAAAAAAAAAwQwAAGNsaXBib2FyZC9kcmF3aW5ncy9fcmVscy9kcmF3aW5nMS54
bWwucmVsc1BLBQYAAAAABQAFAGcBAADEDQAAAAA=
">
   <v:shape id="Shape_x0020_64313" o:spid="_x0000_s1042" style='position:absolute;
    width:91;height:198;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="9144,19812" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQCJTFwFyAAAAN4AAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9BS8NA
FITvQv/D8gre7CZWQondltYqKohgtPT6yL5m02bfptk1jf/eFYQeh5n5hpkvB9uInjpfO1aQThIQ
xKXTNVcKvj6fbmYgfEDW2DgmBT/kYbkYXc0x1+7MH9QXoRIRwj5HBSaENpfSl4Ys+olriaO3d53F
EGVXSd3hOcJtI2+TJJMWa44LBlt6MFQei2+r4HH9nib8RuvnfrvbBFNkw+H1pNT1eFjdgwg0hEv4
v/2iFWR303QKf3fiFZCLXwAAAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAA
AAAAAAAAAAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUB
AAALAAAAAAAAAAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQCJTFwFyAAAAN4A
AAAPAAAAAAAAAAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA/AIAAAAA
" path="m,l9144,r,19812l,19812,,e" fillcolor="#7b7b7b" stroked="f"
    strokeweight="0">
    <v:stroke miterlimit="66585f" joinstyle="miter" endcap="round"/>
    <v:path arrowok="t" textboxrect="0,0,9144,19812"/>
   </v:shape><v:shape id="Shape_x0020_64314" o:spid="_x0000_s1043" style='position:absolute;
    top:198;width:91;height:16309;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="9144,1630934" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQByB8LWyAAAAN4AAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Ba8JA
FITvQv/D8gq9SN1YRUp0FS2VBqvQpj14fGSfSTT7NmS3Jv57tyB4HGbmG2a26EwlztS40rKC4SAC
QZxZXXKu4Pdn/fwKwnlkjZVlUnAhB4v5Q2+GsbYtf9M59bkIEHYxKii8r2MpXVaQQTewNXHwDrYx
6INscqkbbAPcVPIliibSYMlhocCa3grKTumfUbBNdnV6/Eo+Nu+t7K94u7ft516pp8duOQXhqfP3
8K2daAWT8Wg4hv874QrI+RUAAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAA
AAAAAAAAAAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUB
AAALAAAAAAAAAAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQByB8LWyAAAAN4A
AAAPAAAAAAAAAAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA/AIAAAAA
" path="m,l9144,r,1630934l,1630934,,e" fillcolor="#7b7b7b" stroked="f"
    strokeweight="0">
    <v:stroke miterlimit="66585f" joinstyle="miter" endcap="round"/>
    <v:path arrowok="t" textboxrect="0,0,9144,1630934"/>
   </v:shape><w:wrap type="square"/>
  </v:group><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_54721"
   o:spid="_x0000_s1038" style='position:absolute;left:0;text-align:left;
   margin-left:376.65pt;margin-top:-4.3pt;width:.7pt;height:130pt;z-index:251662336;
   mso-position-horizontal-relative:text;mso-position-vertical-relative:text'
   coordsize="91,16507" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Shape_x0020_64317" o:spid="_x0000_s1039" style='position:absolute;
    width:91;height:198;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="9144,19812" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQD2d1oGyAAAAN4AAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9BS8NA
FITvQv/D8gre7CYqUWK3xWqlLRTBqPT6yL5mo9m3aXabxn/vFgSPw8x8w0zng21ET52vHStIJwkI
4tLpmisFH+8vV/cgfEDW2DgmBT/kYT4bXUwx1+7Eb9QXoRIRwj5HBSaENpfSl4Ys+olriaO3d53F
EGVXSd3hKcJtI6+TJJMWa44LBlt6MlR+F0erYLl4TRPe0mLVf+6egymy4WtzUOpyPDw+gAg0hP/w
X3utFWS3N+kdnO/EKyBnvwAAAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAA
AAAAAAAAAAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUB
AAALAAAAAAAAAAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQD2d1oGyAAAAN4A
AAAPAAAAAAAAAAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA/AIAAAAA
" path="m,l9144,r,19812l,19812,,e" fillcolor="#7b7b7b" stroked="f"
    strokeweight="0">
    <v:stroke miterlimit="66585f" joinstyle="miter" endcap="round"/>
    <v:path arrowok="t" textboxrect="0,0,9144,19812"/>
   </v:shape><v:shape id="Shape_x0020_64318" o:spid="_x0000_s1040" style='position:absolute;
    top:198;width:91;height:16309;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="9144,1630934" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l9144,r,1630934l,1630934,,e" fillcolor="#7b7b7b" stroked="f"
    strokeweight="0">
    <v:stroke miterlimit="66585f" joinstyle="miter" endcap="round"/>
    <v:path arrowok="t" textboxrect="0,0,9144,1630934"/>
   </v:shape><w:wrap type="square"/>
  </v:group><![endif]--><img width="1" height="173" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image003.gif" />Pruritus (incl. Urticaria Stevens-Johnson uncommon cases syndrome/ Toxic of generalised Epidermal pruritus), rash, Necrolysis , ecchymosis, DRESS syndrome&nbsp; cutaneous and subcutaneous haemorrhage</p></td></tr><tr><td colspan="5"><p><strong>Musculoskeletal and connective tissue disorders</strong>&nbsp;</p><p>&nbsp;</p></td></tr><tr><td><p>Pain in extremity<sup>A</sup></p></td><td><p>Haemarthrosis</p></td><td><p>Muscle haemorrhage</p></td><td><p>&nbsp;</p></td><td><p>Compartment syndrome secondary to a bleeding</p></td></tr><tr><td colspan="5"><p><strong>Renal and urinary disorders</strong>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p></td></tr><tr><td><p>Urogenital tract haemorrhage (incl.</p><p>haematuria and menorrhagia<sup>B</sup>), renal impairment (incl. blood creatinine</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Renal failure/acute renal failure secondary to a bleeding sufficient to cause hypoperfusion</p></td></tr><tr><td><p>increased, blood urea increased)&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>General disorders and administration site conditions</strong>&nbsp;</p><p>&nbsp; &nbsp;</p></td></tr><tr><td><p>Fever<sup>A</sup>, peripheral oedema, decreased general strength and energy (incl.</p><p>fatigue and asthenia)</p></td><td><p>Feeling unwell</p><p>(incl. malaise)&nbsp;</p></td><td><p>Localised oedema<sup>A</sup></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Investigations</strong>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Increased LDH<sup>A</sup>, increased lipase<sup>A</sup>, increased amylase<sup>A</sup></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Injury, poisoning and procedural complications</strong>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p></td></tr><tr><td colspan="5"><p><!--[if gte vml 1]><v:group id="Group_x0020_60075" o:spid="_x0000_s1035"
   style='position:absolute;margin-left:93.85pt;margin-top:-4.4pt;width:.7pt;
   height:130pt;z-index:251663360;mso-position-horizontal-relative:text;
   mso-position-vertical-relative:text' coordsize="91,16507" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Shape_x0020_64321" o:spid="_x0000_s1036" style='position:absolute;
    width:91;height:198;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="9144,19812" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l9144,r,19812l,19812,,e" fillcolor="#7b7b7b" stroked="f"
    strokeweight="0">
    <v:stroke miterlimit="66585f" joinstyle="miter" endcap="round"/>
    <v:path arrowok="t" textboxrect="0,0,9144,19812"/>
   </v:shape><v:shape id="Shape_x0020_64322" o:spid="_x0000_s1037" style='position:absolute;
    top:198;width:91;height:16309;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="9144,1630934" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l9144,r,1630934l,1630934,,e" fillcolor="#7b7b7b" stroked="f"
    strokeweight="0">
    <v:stroke miterlimit="66585f" joinstyle="miter" endcap="round"/>
    <v:path arrowok="t" textboxrect="0,0,9144,1630934"/>
   </v:shape><w:wrap type="square"/>
  </v:group><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_60076"
   o:spid="_x0000_s1032" style='position:absolute;margin-left:188.2pt;
   margin-top:-4.4pt;width:.7pt;height:130pt;z-index:251664384;
   mso-position-horizontal-relative:text;mso-position-vertical-relative:text'
   coordsize="91,16507" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Shape_x0020_64325" o:spid="_x0000_s1033" style='position:absolute;
    width:91;height:198;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="9144,19812" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l9144,r,19812l,19812,,e" fillcolor="#7b7b7b" stroked="f"
    strokeweight="0">
    <v:stroke miterlimit="66585f" joinstyle="miter" endcap="round"/>
    <v:path arrowok="t" textboxrect="0,0,9144,19812"/>
   </v:shape><v:shape id="Shape_x0020_64326" o:spid="_x0000_s1034" style='position:absolute;
    top:198;width:91;height:16309;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="9144,1630934" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l9144,r,1630934l,1630934,,e" fillcolor="#7b7b7b" stroked="f"
    strokeweight="0">
    <v:stroke miterlimit="66585f" joinstyle="miter" endcap="round"/>
    <v:path arrowok="t" textboxrect="0,0,9144,1630934"/>
   </v:shape><w:wrap type="square"/>
  </v:group><![endif]--><img width="1" height="173" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image004.gif" /><!--[if gte vml 1]><v:group
   id="Group_x0020_60077" o:spid="_x0000_s1029" style='position:absolute;
   margin-left:282.4pt;margin-top:-4.4pt;width:.7pt;height:130pt;z-index:251665408;
   mso-position-horizontal-relative:text;mso-position-vertical-relative:text'
   coordsize="91,16507" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Shape_x0020_64329" o:spid="_x0000_s1030" style='position:absolute;
    width:91;height:198;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="9144,19812" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l9144,r,19812l,19812,,e" fillcolor="#7b7b7b" stroked="f"
    strokeweight="0">
    <v:stroke miterlimit="66585f" joinstyle="miter" endcap="round"/>
    <v:path arrowok="t" textboxrect="0,0,9144,19812"/>
   </v:shape><v:shape id="Shape_x0020_64330" o:spid="_x0000_s1031" style='position:absolute;
    top:198;width:91;height:16309;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="9144,1630934" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l9144,r,1630934l,1630934,,e" fillcolor="#7b7b7b" stroked="f"
    strokeweight="0">
    <v:stroke miterlimit="66585f" joinstyle="miter" endcap="round"/>
    <v:path arrowok="t" textboxrect="0,0,9144,1630934"/>
   </v:shape><w:wrap type="square"/>
  </v:group><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_60078"
   o:spid="_x0000_s1026" style='position:absolute;margin-left:376.65pt;
   margin-top:-4.4pt;width:.7pt;height:130pt;z-index:251666432;
   mso-position-horizontal-relative:text;mso-position-vertical-relative:text'
   coordsize="91,16507" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Shape_x0020_64333" o:spid="_x0000_s1027" style='position:absolute;
    width:91;height:198;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="9144,19812" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQDC+QBlyAAAAN4AAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9BS8NA
FITvQv/D8gre7KZGQondltYqKohgtPT6yL5m02bfptk1jf/eFYQeh5n5hpkvB9uInjpfO1YwnSQg
iEuna64UfH0+3cxA+ICssXFMCn7Iw3Ixuppjrt2ZP6gvQiUihH2OCkwIbS6lLw1Z9BPXEkdv7zqL
IcqukrrDc4TbRt4mSSYt1hwXDLb0YKg8Ft9WweP6fZrwG62f++1uE0yRDYfXk1LX42F1DyLQEC7h
//aLVpDdpWkKf3fiFZCLXwAAAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAA
AAAAAAAAAAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUB
AAALAAAAAAAAAAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQDC+QBlyAAAAN4A
AAAPAAAAAAAAAAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA/AIAAAAA
" path="m,l9144,r,19812l,19812,,e" fillcolor="#7b7b7b" stroked="f"
    strokeweight="0">
    <v:stroke miterlimit="66585f" joinstyle="miter" endcap="round"/>
    <v:path arrowok="t" textboxrect="0,0,9144,19812"/>
   </v:shape><v:shape id="Shape_x0020_64334" o:spid="_x0000_s1028" style='position:absolute;
    top:198;width:91;height:16309;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="9144,1630934" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l9144,r,1630934l,1630934,,e" fillcolor="#7b7b7b" stroked="f"
    strokeweight="0">
    <v:stroke miterlimit="66585f" joinstyle="miter" endcap="round"/>
    <v:path arrowok="t" textboxrect="0,0,9144,1630934"/>
   </v:shape><w:wrap type="square"/>
  </v:group><![endif]--><img width="1" height="173" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image003.gif" />Postprocedural Vascular</p><p>haemorrhage (incl. pseudoaneurysm<sup>C</sup> postoperative anaemia, and wound haemorrhage), contusion, wound secretion<sup>A</sup></p></td></tr><tr><td colspan="5"><p>A: observed in prevention of VTE in adult patients undergoing elective hip or knee replacement surgery</p><p>B: observed in treatment of DVT, PE and prevention of recurrence as very common in women &lt; 55 years</p><p>C: observed as uncommon in prevention of atherothrombotic events in patients after an ACS</p><p>(following percutaneous coronary intervention)</p><p>* A pre-specified selective approach to adverse event collection was applied. As incidence of adverse reactions did not increase and no new adverse reaction was identified, COMPASS study data were not included for frequency calculation in this table.</p></td></tr></tbody></table><p>Description of selected adverse reactions&nbsp;</p><p>Due to the pharmacological mode of action, the use of Xarelto may be associated with an increased risk of occult or overt bleeding from any tissue or organ which may result in post haemorrhagic anaemia. The signs, symptoms, and severity (including fatal outcome) will vary according to the location and degree or extent of the bleeding and/or anaemia (see section 4.9 &ldquo;Management of bleeding&rdquo;). In the clinical studies mucosal bleedings (i.e. epistaxis, gingival, gastrointestinal, genito urinary including abnormal vaginal or increased menstrual bleeding) and anaemia were seen more frequently during long term rivaroxaban treatment compared with VKA treatment. Thus, in addition to adequate clinical surveillance, laboratory testing of haemoglobin/haematocrit could be of value to detect occult bleeding and quantify the clinical relevance of overt bleeding, as judged to be appropriate. The risk of bleedings may be increased in certain patient groups, e.g. those patients with uncontrolled severe arterial hypertension and/or on concomitant treatment affecting haemostasis (see section 4.4 &ldquo;Haemorrhagic risk&rdquo;). Menstrual bleeding may be intensified and/or prolonged. Haemorrhagic complications may present as weakness, paleness, dizziness, headache or unexplained swelling, dyspnoea and unexplained shock. In some cases as a consequence of anaemia, symptoms of cardiac ischaemia like chest pain or angina pectoris have been observed.&nbsp;</p><p>Known complications secondary to severe bleeding such as compartment syndrome and renal failure due to hypoperfusion have been reported for Xarelto. Therefore, the possibility of haemorrhage is to be considered in evaluating the condition in any anticoagulated patient.</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>Reporting of suspected adverse reactions&nbsp;</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side affects; you can help provide more information on the safety of this medicine.</p><p><strong><em>&bull; </em>Saudi Arabia<em>: </em></strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>The National Pharmacovigilance and Drug Safety Centre (NPC) o Fax: +966-11-205-7662 o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o Toll free phone: 8002490000 o E-mail: npc.drug@sfda.gov.sa o Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>o Other GCC States: </strong></p><p>&nbsp;Please contact the relevant competent authority.<strong> </strong></p><p>Summary of the safety profile&nbsp;</p><p>The safety of rivaroxaban has been evaluated in thirteen phase III studies including 53,103 patients exposed to rivaroxaban (see Table 1).</p><p><strong>Table 1: Number of patients studied, total daily dose and maximum treatment duration in phase III studies</strong>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Indication</strong>&nbsp;</p></td><td><p><strong>Number of patients*</strong>&nbsp;</p></td><td><p><strong>Total daily dose</strong>&nbsp;</p></td><td><p><strong>Maximum treatment duration</strong>&nbsp;</p></td></tr><tr><td><p>Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or</p><p>knee replacement surgery</p></td><td><p>6,097</p></td><td><p>10 mg</p></td><td><p>39 days</p></td></tr><tr><td><p>Prevention of VTE in medically ill patients</p></td><td><p>3,997</p></td><td><p>10 mg</p></td><td><p>39 days</p></td></tr><tr><td><p>Treatment of DVT, PE and prevention of recurrence</p></td><td><p>6,790</p></td><td><p>Day 1 - 21: 30 mg Day 22 and onwards: 20 mg</p><p>After at least 6 months: 10 mg or 20 mg</p></td><td><p>21 months</p></td></tr><tr><td><p>Prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation</p></td><td><p>7,750</p></td><td><p>20 mg</p></td><td><p>41 months</p></td></tr><tr><td><p>Prevention of atherothrombotic events in patients after an acute coronary syndrome (ACS)</p></td><td><p>10,225</p></td><td><p>5 mg or 10 mg respectively, coadministered with either ASA or ASA plus clopidogrel or ticlopidine</p></td><td><p>31 months</p></td></tr><tr><td><p>Prevention of atherothrombotic events in patients with CAD/PAD</p></td><td><p>18,244</p></td><td><p>5 mg coadministered with ASA or 10 mg alone</p></td><td><p>47 months</p></td></tr><tr><td colspan="4"><p>* Patients exposed to at least one dose of rivaroxaban</p></td></tr></tbody></table><p>The most commonly reported adverse reactions in patients receiving rivaroxaban were bleedings (see section 4.4. and &#39;Description of selected adverse reactions&#39; below) (Table 2). The most commonly reported bleedings were epistaxis (4.5 %) and gastrointestinal tract haemorrhage (3.8 %).</p><p><strong>Table 2: Bleeding* and anaemia events rates in patients exposed to rivaroxaban across the completed phase III studies</strong>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Indication</strong>&nbsp;</p></td><td><p><strong>Any bleeding</strong>&nbsp;</p></td><td><p><strong>Anaemia</strong>&nbsp;</p></td></tr><tr><td><p>Prevention of VTE in adult patients undergoing elective hip or knee replacement surgery</p></td><td><p>6.8% of patients</p></td><td><p>5.9% of patients</p></td></tr><tr><td><p>Prevention of VTE in medically ill patients</p></td><td><p>12.6% of patients</p></td><td><p>2.1% of patients</p></td></tr><tr><td><p>Treatment of DVT, PE and prevention of recurrence</p></td><td><p>23% of patients</p></td><td><p>1.6% of patients</p></td></tr><tr><td><p>Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation</p></td><td><p>28 per 100 patient years</p></td><td><p>2.5 per 100 patient years</p></td></tr><tr><td><p>Prevention of atherothrombotic events in patients after an ACS</p></td><td><p>22 per 100 patient years</p></td><td><p>1.4 per 100 patient years</p></td></tr><tr><td><p>Prevention of atherothrombotic events in patients with CAD/PAD</p></td><td><p>6.7 per 100 patient years</p></td><td><p>0.15 per 100 patient years**&nbsp;</p></td></tr><tr><td colspan="3"><p>* For all rivaroxaban studies all bleeding events are collected, reported and adjudicated.&nbsp; ** In the COMPASS study, there is a low anaemia incidence as a selective approach to adverse event collection was applied</p></td></tr></tbody></table><p>Tabulated list of adverse reactions&nbsp;</p><p>The frequencies of adverse reactions reported with Xarelto are summarised in Table 3 below by system organ class (in MedDRA) and by frequency.&nbsp;</p><p>Frequencies are defined as: very common (&ge; 1/10) common (&ge; 1/100 to &lt; 1/10) &nbsp;uncommon (&ge; 1/1,000 to &lt; 1/100) &nbsp;rare (&ge; 1/10,000 to &lt; 1/1,000) very rare ( &lt; 1/10,000) not known (cannot be estimated from the available data)</p><p><strong>Table 3: All adverse reactions reported in patients in phase III clinical trials or through post-marketing use*&nbsp; </strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Common</strong>&nbsp;</p></td><td><p><strong>Uncommon</strong>&nbsp;</p></td><td><p><strong>Rare</strong>&nbsp;</p></td><td><p><strong>Very rare</strong>&nbsp;</p></td><td><p><strong>Not known</strong>&nbsp;</p></td></tr><tr><td colspan="3"><p><strong>Blood and lymphatic system disorders</strong>&nbsp;</p><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Anaemia (incl.</p><p>respective laboratory</p></td><td><p>Thrombocytosis</p><p>(incl. platelet count increased)<sup>A</sup>,</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>parameters)</p></td><td><p>Thrombocytopenia</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Immune system disorders</strong>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Allergic reaction, dermatitis allergic,</p><p>Angioedema and allergic oedema</p></td><td><p>&nbsp;</p></td><td><p>Anaphylactic reactions including anaphylactic shock&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Nervous system disorders</strong>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p></td></tr><tr><td><p>Dizziness, headache</p></td><td><p>Cerebral and intracranial haemorrhage, syncope</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Eye disorders</strong>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p></td></tr><tr><td><p>Eye haemorrhage (incl. conjunctival haemorrhage)</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Cardiac disorders</strong>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Tachycardia</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Vascular disorders</strong>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p></td></tr><tr><td colspan="5"><p>Hypotension, haematoma</p></td></tr><tr><td colspan="5"><p><strong>Respiratory, thoracic and mediastinal disorders</strong>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p></td></tr><tr><td><p>Epistaxis, haemoptysis</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Gastrointestinal disorders</strong>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p></td></tr><tr><td><p>Gingival bleeding, gastrointestinal tract haemorrhage</p><p>(incl. rectal haemorrhage), gastrointestinal and abdominal pains, dyspepsia, nausea, constipation<sup>A</sup>,</p></td><td><p>Dry mouth</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>diarrhoea, vomiting<sup>A</sup></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Hepatobiliary disorders</strong>&nbsp;</p><p>&nbsp; &nbsp;</p></td></tr><tr><td><p>Increase in transaminases</p></td><td><p>Hepatic impairment, Increased bilirubin, increased blood alkaline phosphatase<sup>A</sup>, increased GGT<sup>A</sup></p></td><td><p>Jaundice, Bilirubin conjugated increased (with or without concomitant increase of ALT),</p><p>Cholestasis, Hepatitis (incl. hepatocellular injury)</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Skin and subcutaneous tissue disorders</strong>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p></td></tr><tr><td colspan="5"><p><!--[if gte vml 1]><v:group id="Group_x0020_54714" o:spid="_x0000_s1047"
   style='position:absolute;left:0;text-align:left;margin-left:93.85pt;
   margin-top:-4.3pt;width:.7pt;height:130pt;z-index:251659264;
   mso-position-horizontal-relative:text;mso-position-vertical-relative:text'
   coordsize="91,16507" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Shape_x0020_64305" o:spid="_x0000_s1048" style='position:absolute;
    width:91;height:198;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="9144,19812" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l9144,r,19812l,19812,,e" fillcolor="#7b7b7b" stroked="f"
    strokeweight="0">
    <v:stroke miterlimit="66585f" joinstyle="miter" endcap="round"/>
    <v:path arrowok="t" textboxrect="0,0,9144,19812"/>
   </v:shape><v:shape id="Shape_x0020_64306" o:spid="_x0000_s1049" style='position:absolute;
    top:198;width:91;height:16309;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="9144,1630934" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l9144,r,1630934l,1630934,,e" fillcolor="#7b7b7b" stroked="f"
    strokeweight="0">
    <v:stroke miterlimit="66585f" joinstyle="miter" endcap="round"/>
    <v:path arrowok="t" textboxrect="0,0,9144,1630934"/>
   </v:shape><w:wrap type="square"/>
  </v:group><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_54716"
   o:spid="_x0000_s1044" style='position:absolute;left:0;text-align:left;
   margin-left:188.2pt;margin-top:-4.3pt;width:.7pt;height:130pt;z-index:251660288;
   mso-position-horizontal-relative:text;mso-position-vertical-relative:text'
   coordsize="91,16507" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Shape_x0020_64309" o:spid="_x0000_s1045" style='position:absolute;
    width:91;height:198;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="9144,19812" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l9144,r,19812l,19812,,e" fillcolor="#7b7b7b" stroked="f"
    strokeweight="0">
    <v:stroke miterlimit="66585f" joinstyle="miter" endcap="round"/>
    <v:path arrowok="t" textboxrect="0,0,9144,19812"/>
   </v:shape><v:shape id="Shape_x0020_64310" o:spid="_x0000_s1046" style='position:absolute;
    top:198;width:91;height:16309;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="9144,1630934" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l9144,r,1630934l,1630934,,e" fillcolor="#7b7b7b" stroked="f"
    strokeweight="0">
    <v:stroke miterlimit="66585f" joinstyle="miter" endcap="round"/>
    <v:path arrowok="t" textboxrect="0,0,9144,1630934"/>
   </v:shape><w:wrap type="square"/>
  </v:group><![endif]--><img width="1" height="173" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /><!--[if gte vml 1]><v:group
   id="Group_x0020_54720" o:spid="_x0000_s1041" style='position:absolute;
   left:0;text-align:left;margin-left:282.4pt;margin-top:-4.3pt;width:.7pt;
   height:130pt;z-index:251661312;mso-position-horizontal-relative:text;
   mso-position-vertical-relative:text' coordsize="91,16507" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEApQjQYQ8DAAD9CgAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWzsVltvmzAUfp+0/4B4b4GEkItKq7Xb
+jKtVdP9ANeYgGZsZDsp2a/f8Q1IqnbdJm0PWythY5/zne9cw9lF19BgR4SsOcvD5DQOA8IwL2q2
ycMv9x9PFmEgFWIFopyRPNwTGV6cv31zhlYbgdqqxgEgMLlCeVgp1a6iSOKKNEie8pYwuCu5aJCC
V7GJCoEeAbmh0SSOs6hBNQvPB6j3SKFgK+pfgKIcfyXFFWI7JAGS4tX4xHGk+PeR0YrtrkW7bm+F
Zo4/725FUBd5CJFjqIEQhZG7cGLwGh1pbQaArhSNludlGXR5mM6n08kSsPawn6XxYjGzeKRTAQaB
xULfYrhOslk8zdw1rm5+AICrDy9BAEVLBTYjemar+T3j9SydT3rPrwXftoE9+qtBsPGLXSZ6x5dJ
mg6xm6eZFnjGcdlar58mOkunydQne12hlgT2yLusVXzSvbp09XKU7gOiPsUjmstFMjkgCRW3leqa
cFM0aPdJKmN2U/gdqvwOd8xvBcEqoKZIlXkK83zQT6PfIqX1tM96GzzmoaVRQaEZFvqq4Ttyz42Q
0tU6og9hHG4pG0tZIKhYYwsE/bVfWwPWi1l7NoJexK9W1Np9rdyhWbCvPTSJ772Gw3FcKdMBACsY
tXkoWGGmVFMrIgJaNxCSOMniAdeA+RSrbm1qR3WXvNjrYD3AClMCxqy6gUdJOaBjWrdhUHHx7ejM
5INKtVZ7SmxyNAhhxS0S6A6AKNLTGYmT9TtXHGAQXBgsbiVZt3eQdBtFT0lqSA1G2R0pYWyZHOoD
KTYPVxQ4Il0l5s/4jGhbIXfqbDlRY9HgaP2yprSHTIzqAeT8Uv87BCdsvCpLYNlrxlYTOza2SsFX
SIWvVfCTeCVjmbNBn8GPlKdpfQVx28ovNzTMBTu9h4ZONZCZ8D/d0H1lAlc3dEdNnU3j5dSgAzk/
EMbl94fa2vHQTg6tO24wX+DD7WEb9h3rBf21X48b+8BzL+TXseXk1ZKHpiGg/5v7n2tuyLr7TomO
PvzMkHIfqvrrcvx+/h0AAP//AwBQSwMEFAAGAAgAAAAhAJJ9h+AdBwAASSAAABoAAABjbGlwYm9h
cmQvdGhlbWUvdGhlbWUxLnhtbOxZS28bNxC+F+h/WOy9sWS9YiNyYMly3MQvREqKHCmJ2mXMXS5I
yo5uRXLqpUCBtOihAXrroSgaoAEa9NIfY8BBm/6IDrkvUqLiB1wgKGwBxu7sN8PhzOzM7PDO3WcR
9Y4xF4TFbb96q+J7OB6xMYmDtv9osP3Zbd8TEsVjRFmM2/4MC//uxqef3EHrI0qSIUN8PAhxhD0Q
FIt11PZDKZP1lRUxAjISt1iCY3g2YTxCEm55sDLm6AQWiOjKaqXSXIkQif0NkCiVoB6Ff7EUijCi
vK/EYC9GEax+MJmQEdbY8VFVIcRMdCn3jhFt+yBzzE4G+Jn0PYqEhAdtv6L//JWNOytoPWOicgmv
wbet/zK+jGF8tKrX5MGwWLReb9Sbm4V8DaByEddr9Zq9ZiFPA9BoBDtNdbFltla79QxrgNJLh+yt
1latauEN+bUFnTcb6mfhNSiVX1/Ab293wYoWXoNSfGMB3+isdbZs+RqU4psL+FZlc6vesuRrUEhJ
fLSArjSatW6+2wIyYXTHCV9r1Ldbq5nwEgXRUESXWmLCYrks1iL0lPFtACggRZLEnpwleIJGEJNd
RMmQE2+XBCEEXoJiJoBcWa1sV2rwX/3q+kp7FK1jZHArvUATsUBS+nhixEki2/59kOobkLO3b0+f
vzl9/vvpixenz3/N1taiLL4dFAcm3/ufvvnn1Zfe37/9+P7lt+nS83hh4t/98tW7P/78kHjYcWmK
s+9ev3vz+uz7r//6+aVD+iZHQxM+IBEW3j4+8R6yCDbo0B8P+eU4BiEiJsdmHAgUI7WKQ35PhhZ6
f4YocuA62LbjYw6pxgW8N31qKdwP+VQSh8QHYWQB9xijHcadVnig1jLMPJjGgXtxPjVxDxE6dq3d
RbHl5d40gRxLXCK7IbbUPKQolijAMZaeesaOMHbs7gkhll33yIgzwSbSe0K8DiJOkwzI0IqmkmmH
ROCXmUtB8Ldlm73HXodR16638LGNhHcDUYfyA0wtM95DU4kil8gBiqhp8F0kQ5eS/RkfmbiekODp
AFPm9cZYCBfPAYf9Gk5/AGnG7fY9OotsJJfkyCVzFzFmIrfYUTdEUeLC9kkcmtjPxRGEKPIOmXTB
95j9hqh78AOKl7r7McGWu8/PBo8gw5oqlQGinky5w5f3MLPitz+jE4RdqWaTR1aK3eTEGR2daWCF
9i7GFJ2gMcbeo88dGnRYYtm8VPp+CFllB7sC6z6yY1Xdx1hgTzc3i3lylwgrZPs4YEv02ZvNJZ4Z
iiPEl0neB6+bNu9BqYtcAXBAR0cmcJ9Avwfx4jTKgQAZRnAvlXoYIquAqXvhjtcZt/x3kXcM3sun
lhoXeC+BB1+aBxK7yfNB2wwQtRYoA2aAoMtwpVtgsdxfsqjiqtmmTr6J/dKWboDuyGp6IhKf2wHN
9T6N/673gQ7j7IdXjpftevodt2ArWV2y01mWTHbm+ptluPmupsv4mHz8Tc0WmsaHGOrIYsa66Wlu
ehr/f9/TLHufbzqZZf3GTSfjQ4dx08lkw5Xr6WTK5gX6GjXwSAc9euwTLZ36TAilfTmjeFfowY+A
75nxNhAVn55u4mIKmIRwqcocLGDhAo40j8eZ/ILIsB+iBKZDVV8JCUQmOhBewgQMjTTZKVvh6TTa
Y+N02FmtqsFmWlkFkiW90ijoMKiSKbrZKgd4hXitbaAHrbkCivcyShiL2UrUHEq0cqIykh7rgtEc
SuidXYsWaw4tbivxuasWtADVCq/AB7cHn+ltv1EHFmCCeRw052Plp9TVuXe1M6/T08uMaUUANNh5
BJSeXlO6Lt2e2l0aahfwtKWEEW62EtoyusETIXwGZ9GpqBdR47K+XitdaqmnTKHXg9Aq1Wjd/pAW
V/U18M3nBhqbmYLG3knbb9YaEDIjlLT9CQyN4TJKIHaE+uZCNIDjlpHk6Qt/lcyScCG3kAhTg+uk
k2aDiEjMPUqitq+2X7iBxjqHaN2qq5AQPlrl1iCtfGzKgdNtJ+PJBI+k6XaDoiyd3kKGT3OF86lm
vzpYcbIpuLsfjk+8IZ3yhwhCrNGqKgOOiYCzg2pqzTGBw7AikZXxN1eYsrRrnkbpGErpiCYhyiqK
mcxTuE7lhTr6rrCBcZftGQxqmCQrhMNAFVjTqFY1LapGqsPSqns+k7KckTTLmmllFVU13VnMWiEv
A3O2vFqRN7TKTQw5zazwaeqeT7lrea6b6xOKKgEGL+znqLoXKAiGauVilmpK48U0rHJ2RrVrR77B
c1S7SJEwsn4zFztnt6JGOJcD4pUqP/DNRy2QJnlfqS3tOtjeQ4k3DKptHw6XYTj4DK7geNoH2qqi
rSoaXMGZM5SL9KC47WcXOQWep5QCU8sptRxTzyn1nNLIKY2c0swpTd/TJ6pwiq8OU30vPzCFGpYd
sGa9hX36v/EvAAAA//8DAFBLAwQUAAYACAAAACEAnGZGQbsAAAAkAQAAKgAAAGNsaXBib2FyZC9k
cmF3aW5ncy9fcmVscy9kcmF3aW5nMS54bWwucmVsc4SPzQrCMBCE74LvEPZu0noQkSa9iNCr1AcI
yTYtNj8kUezbG+hFQfCyMLPsN7NN+7IzeWJMk3ccaloBQae8npzhcOsvuyOQlKXTcvYOOSyYoBXb
TXPFWeZylMYpJFIoLnEYcw4nxpIa0cpEfUBXNoOPVuYio2FBqrs0yPZVdWDxkwHii0k6zSF2ugbS
L6Ek/2f7YZgUnr16WHT5RwTLpRcWoIwGMwdKV2edNS1dgYmGff0m3gAAAP//AwBQSwECLQAUAAYA
CAAAACEAu+VIlAUBAAAeAgAAEwAAAAAAAAAAAAAAAAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBL
AQItABQABgAIAAAAIQCtMD/xwQAAADIBAAALAAAAAAAAAAAAAAAAADYBAABfcmVscy8ucmVsc1BL
AQItABQABgAIAAAAIQClCNBhDwMAAP0KAAAfAAAAAAAAAAAAAAAAACACAABjbGlwYm9hcmQvZHJh
d2luZ3MvZHJhd2luZzEueG1sUEsBAi0AFAAGAAgAAAAhAJJ9h+AdBwAASSAAABoAAAAAAAAAAAAA
AAAAbAUAAGNsaXBib2FyZC90aGVtZS90aGVtZTEueG1sUEsBAi0AFAAGAAgAAAAhAJxmRkG7AAAA
JAEAACoAAAAAAAAAAAAAAAAAwQwAAGNsaXBib2FyZC9kcmF3aW5ncy9fcmVscy9kcmF3aW5nMS54
bWwucmVsc1BLBQYAAAAABQAFAGcBAADEDQAAAAA=
">
   <v:shape id="Shape_x0020_64313" o:spid="_x0000_s1042" style='position:absolute;
    width:91;height:198;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="9144,19812" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQCJTFwFyAAAAN4AAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9BS8NA
FITvQv/D8gre7CZWQondltYqKohgtPT6yL5m02bfptk1jf/eFYQeh5n5hpkvB9uInjpfO1aQThIQ
xKXTNVcKvj6fbmYgfEDW2DgmBT/kYbkYXc0x1+7MH9QXoRIRwj5HBSaENpfSl4Ys+olriaO3d53F
EGVXSd3hOcJtI2+TJJMWa44LBlt6MFQei2+r4HH9nib8RuvnfrvbBFNkw+H1pNT1eFjdgwg0hEv4
v/2iFWR303QKf3fiFZCLXwAAAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAA
AAAAAAAAAAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUB
AAALAAAAAAAAAAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQCJTFwFyAAAAN4A
AAAPAAAAAAAAAAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA/AIAAAAA
" path="m,l9144,r,19812l,19812,,e" fillcolor="#7b7b7b" stroked="f"
    strokeweight="0">
    <v:stroke miterlimit="66585f" joinstyle="miter" endcap="round"/>
    <v:path arrowok="t" textboxrect="0,0,9144,19812"/>
   </v:shape><v:shape id="Shape_x0020_64314" o:spid="_x0000_s1043" style='position:absolute;
    top:198;width:91;height:16309;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="9144,1630934" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l9144,r,1630934l,1630934,,e" fillcolor="#7b7b7b" stroked="f"
    strokeweight="0">
    <v:stroke miterlimit="66585f" joinstyle="miter" endcap="round"/>
    <v:path arrowok="t" textboxrect="0,0,9144,1630934"/>
   </v:shape><w:wrap type="square"/>
  </v:group><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_54721"
   o:spid="_x0000_s1038" style='position:absolute;left:0;text-align:left;
   margin-left:376.65pt;margin-top:-4.3pt;width:.7pt;height:130pt;z-index:251662336;
   mso-position-horizontal-relative:text;mso-position-vertical-relative:text'
   coordsize="91,16507" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Shape_x0020_64317" o:spid="_x0000_s1039" style='position:absolute;
    width:91;height:198;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="9144,19812" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l9144,r,19812l,19812,,e" fillcolor="#7b7b7b" stroked="f"
    strokeweight="0">
    <v:stroke miterlimit="66585f" joinstyle="miter" endcap="round"/>
    <v:path arrowok="t" textboxrect="0,0,9144,19812"/>
   </v:shape><v:shape id="Shape_x0020_64318" o:spid="_x0000_s1040" style='position:absolute;
    top:198;width:91;height:16309;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="9144,1630934" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l9144,r,1630934l,1630934,,e" fillcolor="#7b7b7b" stroked="f"
    strokeweight="0">
    <v:stroke miterlimit="66585f" joinstyle="miter" endcap="round"/>
    <v:path arrowok="t" textboxrect="0,0,9144,1630934"/>
   </v:shape><w:wrap type="square"/>
  </v:group><![endif]--><img width="1" height="173" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image003.gif" />Pruritus (incl. Urticaria Stevens-Johnson uncommon cases syndrome/ Toxic of generalised Epidermal pruritus), rash, Necrolysis , ecchymosis, DRESS syndrome&nbsp; cutaneous and subcutaneous haemorrhage</p></td></tr><tr><td colspan="5"><p><strong>Musculoskeletal and connective tissue disorders</strong>&nbsp;</p><p>&nbsp;</p></td></tr><tr><td><p>Pain in extremity<sup>A</sup></p></td><td><p>Haemarthrosis</p></td><td><p>Muscle haemorrhage</p></td><td><p>&nbsp;</p></td><td><p>Compartment syndrome secondary to a bleeding</p></td></tr><tr><td colspan="5"><p><strong>Renal and urinary disorders</strong>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p></td></tr><tr><td><p>Urogenital tract haemorrhage (incl.</p><p>haematuria and menorrhagia<sup>B</sup>), renal impairment (incl. blood creatinine</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Renal failure/acute renal failure secondary to a bleeding sufficient to cause hypoperfusion</p></td></tr><tr><td><p>increased, blood urea increased)&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>General disorders and administration site conditions</strong>&nbsp;</p><p>&nbsp; &nbsp;</p></td></tr><tr><td><p>Fever<sup>A</sup>, peripheral oedema, decreased general strength and energy (incl.</p><p>fatigue and asthenia)</p></td><td><p>Feeling unwell</p><p>(incl. malaise)&nbsp;</p></td><td><p>Localised oedema<sup>A</sup></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Investigations</strong>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Increased LDH<sup>A</sup>, increased lipase<sup>A</sup>, increased amylase<sup>A</sup></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Injury, poisoning and procedural complications</strong>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p></td></tr><tr><td colspan="5"><p><!--[if gte vml 1]><v:group id="Group_x0020_60075" o:spid="_x0000_s1035"
   style='position:absolute;margin-left:93.85pt;margin-top:-4.4pt;width:.7pt;
   height:130pt;z-index:251663360;mso-position-horizontal-relative:text;
   mso-position-vertical-relative:text' coordsize="91,16507" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Shape_x0020_64321" o:spid="_x0000_s1036" style='position:absolute;
    width:91;height:198;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="9144,19812" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l9144,r,19812l,19812,,e" fillcolor="#7b7b7b" stroked="f"
    strokeweight="0">
    <v:stroke miterlimit="66585f" joinstyle="miter" endcap="round"/>
    <v:path arrowok="t" textboxrect="0,0,9144,19812"/>
   </v:shape><v:shape id="Shape_x0020_64322" o:spid="_x0000_s1037" style='position:absolute;
    top:198;width:91;height:16309;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="9144,1630934" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l9144,r,1630934l,1630934,,e" fillcolor="#7b7b7b" stroked="f"
    strokeweight="0">
    <v:stroke miterlimit="66585f" joinstyle="miter" endcap="round"/>
    <v:path arrowok="t" textboxrect="0,0,9144,1630934"/>
   </v:shape><w:wrap type="square"/>
  </v:group><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_60076"
   o:spid="_x0000_s1032" style='position:absolute;margin-left:188.2pt;
   margin-top:-4.4pt;width:.7pt;height:130pt;z-index:251664384;
   mso-position-horizontal-relative:text;mso-position-vertical-relative:text'
   coordsize="91,16507" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Shape_x0020_64325" o:spid="_x0000_s1033" style='position:absolute;
    width:91;height:198;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="9144,19812" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l9144,r,19812l,19812,,e" fillcolor="#7b7b7b" stroked="f"
    strokeweight="0">
    <v:stroke miterlimit="66585f" joinstyle="miter" endcap="round"/>
    <v:path arrowok="t" textboxrect="0,0,9144,19812"/>
   </v:shape><v:shape id="Shape_x0020_64326" o:spid="_x0000_s1034" style='position:absolute;
    top:198;width:91;height:16309;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="9144,1630934" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l9144,r,1630934l,1630934,,e" fillcolor="#7b7b7b" stroked="f"
    strokeweight="0">
    <v:stroke miterlimit="66585f" joinstyle="miter" endcap="round"/>
    <v:path arrowok="t" textboxrect="0,0,9144,1630934"/>
   </v:shape><w:wrap type="square"/>
  </v:group><![endif]--><img width="1" height="173" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image004.gif" /><!--[if gte vml 1]><v:group
   id="Group_x0020_60077" o:spid="_x0000_s1029" style='position:absolute;
   margin-left:282.4pt;margin-top:-4.4pt;width:.7pt;height:130pt;z-index:251665408;
   mso-position-horizontal-relative:text;mso-position-vertical-relative:text'
   coordsize="91,16507" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Shape_x0020_64329" o:spid="_x0000_s1030" style='position:absolute;
    width:91;height:198;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="9144,19812" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l9144,r,19812l,19812,,e" fillcolor="#7b7b7b" stroked="f"
    strokeweight="0">
    <v:stroke miterlimit="66585f" joinstyle="miter" endcap="round"/>
    <v:path arrowok="t" textboxrect="0,0,9144,19812"/>
   </v:shape><v:shape id="Shape_x0020_64330" o:spid="_x0000_s1031" style='position:absolute;
    top:198;width:91;height:16309;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="9144,1630934" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l9144,r,1630934l,1630934,,e" fillcolor="#7b7b7b" stroked="f"
    strokeweight="0">
    <v:stroke miterlimit="66585f" joinstyle="miter" endcap="round"/>
    <v:path arrowok="t" textboxrect="0,0,9144,1630934"/>
   </v:shape><w:wrap type="square"/>
  </v:group><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_60078"
   o:spid="_x0000_s1026" style='position:absolute;margin-left:376.65pt;
   margin-top:-4.4pt;width:.7pt;height:130pt;z-index:251666432;
   mso-position-horizontal-relative:text;mso-position-vertical-relative:text'
   coordsize="91,16507" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEAM1EC+RIDAAD9CgAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWzsVltv0zAUfkfiP0R+35K0XXrRsokN
2Ati0zp+gOc4TYRjR7ZbWn49x7dcijYGSPAAmxQ79jnf+c61Ob/cNyzaUalqwXOUniYoopyIouab
HH16eH+yQJHSmBeYCU5zdKAKXV68fnWOVxuJ26omESBwtcI5qrRuV3GsSEUbrE5FSznclUI2WMOr
3MSFxF8AuWHxJEmyuME1Rxc91FuscbSV9S9AMUE+0+Ia8x1WAMnIanjiOTLy+8h4xXc3sl23d9Iw
Jx93dzKqixxB5DhuIEQo9hdeDF7jI61ND7AvZWPkRVlG+xydLSfLbApYhxzN08ksyc4cHt3riIDA
YrGEWwLXaXaWTMM1qW5/AECqd89BAEVHBTYDenZr+D3hdZYkcygR5/mNFNs2ckd/NQgufonPROf4
Mp3N+tjNZ5kReMJx1Tqvv090NptOp8HldYVbGrmj4LJRCUkP6srXy1G6R0RDigc0l4t0MiIJFbdV
+oYKWzR490Fpa3ZThB2uwo7sedhKSnTEbJFq+5T2+WieVr/F2ugZn802+pIjR6OCQrMszFUjdvRB
WCFtqnVAH8LY3zI+lHJAULHWFgiG67C2FqwTc/ZcBINIWJ2os/tSubFZsG88tInvvIbDYVwZNwEA
KwS3OZK8sFOqqTWVEasbCEmSQpn7zDBuwUKK9X5ta0fvr0RxMMF6hBWmBIxZfQuPkglAJ6xuUVQJ
+fXozOaDKb3WB0ZdcgwI5cUdlvgegBg20xnLk/UbTwEMggu9xa2i6/Yeku6iGCgpA2nAGL+nJYwt
m0NzoOTm8ZoBR2yqxP5ZnzFrK+xPvS0vai1aHKNf1ox1kKlVHUHOr8y/R/DC1quyBJadZuI0iWfj
qhR8hVSEWgU/aVCylgXv9Tn8SAWazlcQd638fEPDXHAzrG/omQGyE/6nG7qrTODqh+6gqWG+L6cW
HciFgTAsvz/U1p6HcbJv3WGDhQLvb8dt2HVsEAzXYT1u7JHnQSisQ8vpiyXHpiGg/5v7n2tuyLr/
TomPPvzskPIfqubrcvh+8Q0AAP//AwBQSwMEFAAGAAgAAAAhAJJ9h+AdBwAASSAAABoAAABjbGlw
Ym9hcmQvdGhlbWUvdGhlbWUxLnhtbOxZS28bNxC+F+h/WOy9sWS9YiNyYMly3MQvREqKHCmJ2mXM
XS5Iyo5uRXLqpUCBtOihAXrroSgaoAEa9NIfY8BBm/6IDrkvUqLiB1wgKGwBxu7sN8PhzOzM7PDO
3WcR9Y4xF4TFbb96q+J7OB6xMYmDtv9osP3Zbd8TEsVjRFmM2/4MC//uxqef3EHrI0qSIUN8PAhx
hD0QFIt11PZDKZP1lRUxAjISt1iCY3g2YTxCEm55sDLm6AQWiOjKaqXSXIkQif0NkCiVoB6Ff7EU
ijCivK/EYC9GEax+MJmQEdbY8VFVIcRMdCn3jhFt+yBzzE4G+Jn0PYqEhAdtv6L//JWNOytoPWOi
cgmvwbet/zK+jGF8tKrX5MGwWLReb9Sbm4V8DaByEddr9Zq9ZiFPA9BoBDtNdbFltla79QxrgNJL
h+yt1latauEN+bUFnTcb6mfhNSiVX1/Ab293wYoWXoNSfGMB3+isdbZs+RqU4psL+FZlc6vesuRr
UEhJfLSArjSatW6+2wIyYXTHCV9r1Ldbq5nwEgXRUESXWmLCYrks1iL0lPFtACggRZLEnpwleIJG
EJNdRMmQE2+XBCEEXoJiJoBcWa1sV2rwX/3q+kp7FK1jZHArvUATsUBS+nhixEki2/59kOobkLO3
b0+fvzl9/vvpixenz3/N1taiLL4dFAcm3/ufvvnn1Zfe37/9+P7lt+nS83hh4t/98tW7P/78kHjY
cWmKs+9ev3vz+uz7r//6+aVD+iZHQxM+IBEW3j4+8R6yCDbo0B8P+eU4BiEiJsdmHAgUI7WKQ35P
hhZ6f4YocuA62LbjYw6pxgW8N31qKdwP+VQSh8QHYWQB9xijHcadVnig1jLMPJjGgXtxPjVxDxE6
dq3dRbHl5d40gRxLXCK7IbbUPKQolijAMZaeesaOMHbs7gkhll33yIgzwSbSe0K8DiJOkwzI0Iqm
kmmHROCXmUtB8Ldlm73HXodR16638LGNhHcDUYfyA0wtM95DU4kil8gBiqhp8F0kQ5eS/Rkfmbie
kODpAFPm9cZYCBfPAYf9Gk5/AGnG7fY9OotsJJfkyCVzFzFmIrfYUTdEUeLC9kkcmtjPxRGEKPIO
mXTB95j9hqh78AOKl7r7McGWu8/PBo8gw5oqlQGinky5w5f3MLPitz+jE4RdqWaTR1aK3eTEGR2d
aWCF9i7GFJ2gMcbeo88dGnRYYtm8VPp+CFllB7sC6z6yY1Xdx1hgTzc3i3lylwgrZPs4YEv02ZvN
JZ4ZiiPEl0neB6+bNu9BqYtcAXBAR0cmcJ9Avwfx4jTKgQAZRnAvlXoYIquAqXvhjtcZt/x3kXcM
3sunlhoXeC+BB1+aBxK7yfNB2wwQtRYoA2aAoMtwpVtgsdxfsqjiqtmmTr6J/dKWboDuyGp6IhKf
2wHN9T6N/673gQ7j7IdXjpftevodt2ArWV2y01mWTHbm+ptluPmupsv4mHz8Tc0WmsaHGOrIYsa6
6Wluehr/f9/TLHufbzqZZf3GTSfjQ4dx08lkw5Xr6WTK5gX6GjXwSAc9euwTLZ36TAilfTmjeFfo
wY+A75nxNhAVn55u4mIKmIRwqcocLGDhAo40j8eZ/ILIsB+iBKZDVV8JCUQmOhBewgQMjTTZKVvh
6TTaY+N02FmtqsFmWlkFkiW90ijoMKiSKbrZKgd4hXitbaAHrbkCivcyShiL2UrUHEq0cqIykh7r
gtEcSuidXYsWaw4tbivxuasWtADVCq/AB7cHn+ltv1EHFmCCeRw052Plp9TVuXe1M6/T08uMaUUA
NNh5BJSeXlO6Lt2e2l0aahfwtKWEEW62EtoyusETIXwGZ9GpqBdR47K+XitdaqmnTKHXg9Aq1Wjd
/pAWV/U18M3nBhqbmYLG3knbb9YaEDIjlLT9CQyN4TJKIHaE+uZCNIDjlpHk6Qt/lcyScCG3kAhT
g+ukk2aDiEjMPUqitq+2X7iBxjqHaN2qq5AQPlrl1iCtfGzKgdNtJ+PJBI+k6XaDoiyd3kKGT3OF
86lmvzpYcbIpuLsfjk+8IZ3yhwhCrNGqKgOOiYCzg2pqzTGBw7AikZXxN1eYsrRrnkbpGErpiCYh
yiqKmcxTuE7lhTr6rrCBcZftGQxqmCQrhMNAFVjTqFY1LapGqsPSqns+k7KckTTLmmllFVU13VnM
WiEvA3O2vFqRN7TKTQw5zazwaeqeT7lrea6b6xOKKgEGL+znqLoXKAiGauVilmpK48U0rHJ2RrVr
R77Bc1S7SJEwsn4zFztnt6JGOJcD4pUqP/DNRy2QJnlfqS3tOtjeQ4k3DKptHw6XYTj4DK7geNoH
2qqirSoaXMGZM5SL9KC47WcXOQWep5QCU8sptRxTzyn1nNLIKY2c0swpTd/TJ6pwiq8OU30vPzCF
GpYdsGa9hX36v/EvAAAA//8DAFBLAwQUAAYACAAAACEAnGZGQbsAAAAkAQAAKgAAAGNsaXBib2Fy
ZC9kcmF3aW5ncy9fcmVscy9kcmF3aW5nMS54bWwucmVsc4SPzQrCMBCE74LvEPZu0noQkSa9iNCr
1AcIyTYtNj8kUezbG+hFQfCyMLPsN7NN+7IzeWJMk3ccaloBQae8npzhcOsvuyOQlKXTcvYOOSyY
oBXbTXPFWeZylMYpJFIoLnEYcw4nxpIa0cpEfUBXNoOPVuYio2FBqrs0yPZVdWDxkwHii0k6zSF2
ugbSL6Ek/2f7YZgUnr16WHT5RwTLpRcWoIwGMwdKV2edNS1dgYmGff0m3gAAAP//AwBQSwECLQAU
AAYACAAAACEAu+VIlAUBAAAeAgAAEwAAAAAAAAAAAAAAAAAAAAAAW0NvbnRlbnRfVHlwZXNdLnht
bFBLAQItABQABgAIAAAAIQCtMD/xwQAAADIBAAALAAAAAAAAAAAAAAAAADYBAABfcmVscy8ucmVs
c1BLAQItABQABgAIAAAAIQAzUQL5EgMAAP0KAAAfAAAAAAAAAAAAAAAAACACAABjbGlwYm9hcmQv
ZHJhd2luZ3MvZHJhd2luZzEueG1sUEsBAi0AFAAGAAgAAAAhAJJ9h+AdBwAASSAAABoAAAAAAAAA
AAAAAAAAbwUAAGNsaXBib2FyZC90aGVtZS90aGVtZTEueG1sUEsBAi0AFAAGAAgAAAAhAJxmRkG7
AAAAJAEAACoAAAAAAAAAAAAAAAAAxAwAAGNsaXBib2FyZC9kcmF3aW5ncy9fcmVscy9kcmF3aW5n
MS54bWwucmVsc1BLBQYAAAAABQAFAGcBAADHDQAAAAA=
">
   <v:shape id="Shape_x0020_64333" o:spid="_x0000_s1027" style='position:absolute;
    width:91;height:198;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="9144,19812" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l9144,r,19812l,19812,,e" fillcolor="#7b7b7b" stroked="f"
    strokeweight="0">
    <v:stroke miterlimit="66585f" joinstyle="miter" endcap="round"/>
    <v:path arrowok="t" textboxrect="0,0,9144,19812"/>
   </v:shape><v:shape id="Shape_x0020_64334" o:spid="_x0000_s1028" style='position:absolute;
    top:198;width:91;height:16309;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="9144,1630934" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l9144,r,1630934l,1630934,,e" fillcolor="#7b7b7b" stroked="f"
    strokeweight="0">
    <v:stroke miterlimit="66585f" joinstyle="miter" endcap="round"/>
    <v:path arrowok="t" textboxrect="0,0,9144,1630934"/>
   </v:shape><w:wrap type="square"/>
  </v:group><![endif]--><img width="1" height="173" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image003.gif" />Postprocedural Vascular</p><p>haemorrhage (incl. pseudoaneurysm<sup>C</sup> postoperative anaemia, and wound haemorrhage), contusion, wound secretion<sup>A</sup></p></td></tr><tr><td colspan="5"><p>A: observed in prevention of VTE in adult patients undergoing elective hip or knee replacement surgery</p><p>B: observed in treatment of DVT, PE and prevention of recurrence as very common in women &lt; 55 years</p><p>C: observed as uncommon in prevention of atherothrombotic events in patients after an ACS</p><p>(following percutaneous coronary intervention)</p><p>* A pre-specified selective approach to adverse event collection was applied. As incidence of adverse reactions did not increase and no new adverse reaction was identified, COMPASS study data were not included for frequency calculation in this table.</p></td></tr></tbody></table><p><u>Description of selected adverse reactions&nbsp;</u></p><p>Due to the pharmacological mode of action, the use of Xarelto may be associated with an increased risk of occult or overt bleeding from any tissue or organ which may result in post haemorrhagic anaemia. The signs, symptoms, and severity (including fatal outcome) will vary according to the location and degree or extent of the bleeding and/or anaemia (see section 4.9 &ldquo;Management of bleeding&rdquo;). In the clinical studies mucosal bleedings (i.e. epistaxis, gingival, gastrointestinal, genito urinary including abnormal vaginal or increased menstrual bleeding) and anaemia were seen more frequently during long term rivaroxaban treatment compared with VKA treatment. Thus, in addition to adequate clinical surveillance, laboratory testing of haemoglobin/haematocrit could be of value to detect occult bleeding and quantify the clinical relevance of overt bleeding, as judged to be appropriate. The risk of bleedings may be increased in certain patient groups, e.g. those patients with uncontrolled severe arterial hypertension and/or on concomitant treatment affecting haemostasis (see section 4.4 &ldquo;Haemorrhagic risk&rdquo;). Menstrual bleeding may be intensified and/or prolonged. Haemorrhagic complications may present as weakness, paleness, dizziness, headache or unexplained swelling, dyspnoea and unexplained shock. In some cases as a consequence of anaemia, symptoms of cardiac ischaemia like chest pain or angina pectoris have been observed.&nbsp;</p><p>Known complications secondary to severe bleeding such as compartment syndrome and renal failure due to hypoperfusion have been reported for Xarelto. Therefore, the possibility of haemorrhage is to be considered in evaluating the condition in any anticoagulated patient.</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions&nbsp;</u></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side affects; you can help provide more information on the safety of this medicine.</p><p><strong><em>&bull; </em>Saudi Arabia<em>: </em></strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o Toll free phone: 8002490000<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>o Other GCC States: </strong></p><p>&nbsp;Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Rare cases of overdose up to 600 mg have been reported without bleeding complications or other adverse reactions. Due to limited absorption a ceiling effect with no further increase in average plasma exposure is expected at supratherapeutic doses of 50 mg rivaroxaban or above.&nbsp;</p><p>A specific reversal agent (andexanet alfa) antagonising the pharmacodynamic effect of rivaroxaban is available (refer to the Summary of Product Characteristics of andexanet alfa).</p><p>The use of activated charcoal to reduce absorption in case of rivaroxaban overdose may be considered.&nbsp;</p><p><u>Management of bleeding&nbsp;</u></p><p>Should a bleeding complication arise in a patient receiving rivaroxaban, the next rivaroxaban administration should be delayed or treatment should be discontinued as appropriate. Rivaroxaban has a half-life of approximately 5 to 13 hours (see section 5.2). Management should be individualised according to the severity and location of the haemorrhage. Appropriate symptomatic treatment could be used as needed, such as mechanical compression (e.g. for severe epistaxis), surgical haemostasis with bleeding control procedures, fluid replacement and haemodynamic support, blood products (packed red cells or fresh frozen plasma, depending on associated anaemia or coagulopathy) or platelets.</p><p>If bleeding cannot be controlled by the above measures, either the administration of a specific factor Xa inhibitor reversal agent (andexanet alfa), which antagonises the pharmacodynamic effect of rivaroxaban, or a specific procoagulant reversal agent, such as prothrombin complex concentrate (PCC), activated prothrombin complex concentrate (APCC) or recombinant factor VIIa (r-FVIIa), should be considered. However, there is currently very limited clinical experience with the use of these medicinal products in individuals receiving rivaroxaban. The recommendation is also based on limited non-clinical data. Re-dosing of recombinant factor VIIa shall be considered and titrated depending on improvement of bleeding. Depending on local availability, a consultation with a coagulation expert should be considered in case of major bleedings (see section 5.1).</p><p>Protamine sulphate and vitamin K are not expected to affect the anticoagulant activity of rivaroxaban. There is limited experience with tranexamic acid and no experience with aminocaproic acid and aprotinin in individuals receiving rivaroxaban. There is neither scientific rationale for benefit nor experience with the use of the systemic haemostatic desmopressin in individuals receiving rivaroxaban. Due to the high plasma protein binding rivaroxaban is not expected to be dialysable</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antithrombotic agents, direct factor Xa inhibitors, ATC code:</p><p>B01AF01&nbsp;</p><p><u>Mechanism of action&nbsp;</u></p><p>Rivaroxaban is a highly selective direct factor Xa inhibitor with oral bioavailability. Inhibition of factor Xa interrupts the intrinsic and extrinsic pathway of the blood coagulation cascade, inhibiting both thrombin formation and development of thrombi. Rivaroxaban does not inhibit thrombin (activated factor II) and no effects on platelets have been demonstrated.</p><p><u>Pharmacodynamic effects&nbsp;</u></p><p>Dose-dependent inhibition of factor Xa activity was observed in humans. Prothrombin time (PT) is influenced by rivaroxaban in a dose dependent way with a close correlation to plasma concentrations (r value equals 0.98) if Neoplastin is used for the assay. Other reagents would provide different results. The readout for PT is to be done in seconds, because the INR is only calibrated and validated for coumarins and cannot be used for any other anticoagulant.&nbsp;</p><p>In patients receiving rivaroxaban for treatment of DVT and PE and prevention of recurrence, the 5/95 percentiles for PT (Neoplastin) 2 - 4 hours after tablet intake (i.e. at the time of maximum effect) for 15 mg rivaroxaban twice daily ranged from 17 to 32 s and for 20 mg rivaroxaban once daily from 15 to 30 s. At trough (8 - 16 h after tablet intake) the 5/95 percentiles for 15 mg twice daily ranged from 14 to 24 s and for 20 mg once daily (18 - 30 h after tablet intake) from 13 to 20 s.</p><p>In patients with non-valvular atrial fibrillation receiving rivaroxaban for the prevention of stroke and systemic embolism, the 5/95 percentiles for PT (Neoplastin) 1 - 4 hours after tablet intake (i.e. at the time of maximum effect) in patients treated with 20 mg once daily ranged from 14 to 40 s and in patients with moderate renal impairment treated with 15 mg once daily from 10 to 50 s. At trough (16 - 36 h after tablet intake) the 5/95 percentiles in patients treated with 20 mg once daily ranged from 12 to 26 s and in patients with moderate renal impairment treated with 15 mg once daily from 12 to 26 s.</p><p>In a clinical pharmacology study on the reversal of rivaroxaban pharmacodynamics in healthy adult subjects (n=22), the effects of single doses (50 IU/kg) of two different types of PCCs, a 3factor PCC (Factors II, IX and X) and a 4-factor PCC (Factors II, VII, IX and X) were assessed. The 3-factor PCC reduced mean Neoplastin PT values by approximately 1.0 second within 30 minutes, compared to reductions of approximately 3.5 seconds observed with the 4-factor PCC. In contrast, the 3-factor PCC had a greater and more rapid overall effect on reversing changes in endogenous thrombin generation than the 4-factor PCC (see section 4.9).</p><p>The activated partial thromboplastin time (aPTT) and HepTest are also prolonged dosedependently; however, they are not recommended to assess the pharmacodynamic effect of rivaroxaban. There is no need for monitoring of coagulation parameters during treatment with rivaroxaban in clinical routine. However, if clinically indicated rivaroxaban levels can be measured by calibrated quantitative anti-factor Xa tests (see section 5.2).</p><p><u>Clinical efficacy and safety&nbsp;</u></p><p>Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation&nbsp;</p><p>The Xarelto clinical programme was designed to demonstrate the efficacy of Xarelto for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.&nbsp;</p><p>In the pivotal double-blind ROCKET AF study, 14,264 patients were assigned either to Xarelto 20 mg once daily (15 mg once daily in patients with creatinine clearance 30 - 49 ml/min) or to warfarin titrated to a target INR of 2.5 (therapeutic range 2.0 to 3.0). The median time on treatment was 19 months and overall treatment duration was up to 41 months.&nbsp;</p><p>34.9% of patients were treated with acetylsalicylic acid and 11.4% were treated with class III antiarrhythmic including amiodarone.&nbsp;</p><p>Xarelto was non-inferior to warfarin for the primary composite endpoint of stroke and non-CNS systemic embolism. In the per-protocol population on treatment, stroke or systemic embolism occurred in 188 patients on rivaroxaban (1.71% per year) and 241 on warfarin (2.16% per year) (HR 0.79; 95% CI, 0.66 - 0.96; P&lt;0.001 for non-inferiority). Among all randomised patients analysed according to ITT, primary events occurred in 269 on rivaroxaban (2.12% per year) and 306 on warfarin (2.42% per year) (HR 0.88; 95% CI, 0.74 - 1.03; P&lt;0.001 for non-inferiority; P=0.117 for superiority). Results for secondary endpoints as tested in hierarchical order in the ITT analysis are displayed in Table 4.</p><p>Among patients in the warfarin group, INR values were within the therapeutic range (2.0 to 3.0) a mean of 55% of the time (median, 58%; interquartile range, 43 to 71). The effect of rivaroxaban did not differ across the level of centre TTR (Time in Target INR Range of 2.0 - 3.0) in the equally sized quartiles (P=0.74 for interaction). Within the highest quartile according to centre, the Hazard Ratio (HR) with rivaroxaban versus warfarin was 0.74 (95% CI, 0.49 - 1.12).</p><p>The incidence rates for the principal safety outcome (major and non-major clinically relevant bleeding events) were similar for both treatment groups (see Table 5).</p><p><strong>Table 4: Efficacy results from phase III ROCKET AF</strong>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Study population</strong>&nbsp;</p></td><td colspan="4"><p><strong>ITT analyses of efficacy in patients with non-valvular atrial fibrillation</strong>&nbsp;</p></td></tr><tr><td><p><strong>Treatment dose</strong>&nbsp;</p></td><td><p><strong>Xarelto</strong></p></td><td><p><strong>Warfarin</strong></p></td><td colspan="2"><p><strong>HR (95% CI)</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td><p><strong>20 mg od </strong>&nbsp;</p><p><strong>(15 mg od in patients with moderate renal impairment)</strong>&nbsp; <strong>Event rate (100 pt-</strong></p><p><strong>yr)</strong>&nbsp;</p></td><td><p><strong>titrated to a target </strong></p><p><strong>INR &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2.5 </strong></p><p><strong>(therapeutic &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; range </strong></p><p><strong>2.0 to 3.0)</strong></p><p><strong>Event rate (100 pt-</strong></p><p><strong>yr)</strong>&nbsp;</p></td><td><p><strong>p-value, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; test superiority</strong>&nbsp;</p></td><td><p><strong>for </strong></p></td></tr><tr><td><p>Stroke &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; non-CNS</p><p>systemic embolism</p></td><td><p>269</p><p>&nbsp;</p><p>(2.12)</p></td><td><p>306 (2.42)</p></td><td><p>0.88&nbsp;</p><p>(0.74 - 1.03)</p><p>0.117</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Stroke, non-CNS systemic embolism and vascular</p><p>death</p></td><td><p>572 (4.51)</p></td><td><p>609 (4.81)</p></td><td><p>0.94</p><p>(0.84 - 1.05)</p><p>0.265</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Stroke, non-CNS systemic embolism, vascular death and myocardial infarction</p></td><td><p>659 (5.24)</p></td><td><p>709 (5.65)</p></td><td><p>0.93&nbsp;</p><p>(0.83 - 1.03)</p><p>0.158</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Stroke</p></td><td><p>253&nbsp;</p><p>(1.99)</p></td><td><p>281 (2.22)</p></td><td><p>0.90&nbsp;</p><p>(0.76 - 1.07)</p><p>0.221</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Non-CNS &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; systemic</p><p>embolism</p></td><td><p>20&nbsp;</p><p>(0.16)</p></td><td><p>27</p><p>(0.21)</p></td><td><p>0.74&nbsp;</p><p>(0.42 - 1.32)</p><p>0.308</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Myocardial infarction</p></td><td><p>130 (1.02)</p></td><td><p>142 (1.11)</p></td><td><p>0.91</p><p>(0.72 - 1.16)&nbsp;</p><p>0.464</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Table 5: Safety results from phase III ROCKET AF</strong>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Study population</strong>&nbsp;</p></td><td colspan="4"><p><strong>Patients with non-valvular atrial fibrillation<sup>a)</sup></strong>&nbsp;</p></td></tr><tr><td><p><strong>Treatment dose </strong>&nbsp;</p></td><td><p><strong>Xarelto</strong></p><p><strong>20 mg once a day </strong>&nbsp;</p><p><strong>(15 mg once a day in patients with moderate renal impairment)</strong>&nbsp; <strong>Event rate (100 pt-yr)</strong>&nbsp;</p></td><td><p><strong>Warfarin</strong></p><p><strong>titrated to a target INR of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2.5 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (therapeutic range 2.0 to 3.0)</strong> <strong>Event rate (100 pt-yr)</strong>&nbsp;</p></td><td colspan="2"><p><strong>HR (95% CI)</strong> <strong>p-value </strong>&nbsp;</p></td></tr><tr><td><p>Major and non-major clinically relevant</p></td><td><p>1,475</p><p>(14.91)</p></td><td><p>1,449</p><p>(14.52)</p></td><td colspan="2"><p>1.03 (0.96 - 1.11)</p><p>0.442</p></td></tr><tr><td><p>bleeding events</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td><p>Major bleeding events</p></td><td><p>395 (3.60)</p></td><td><p>386 (3.45)</p></td><td colspan="2"><p>1.04 (0.90 - 1.20)</p><p>0.576</p></td></tr><tr><td><p>Death due to bleeding*</p></td><td><p>27</p><p>(0.24)</p></td><td><p>55</p><p>(0.48)</p></td><td colspan="2"><p>0.50 (0.31 - 0.79)</p><p>0.003</p></td></tr><tr><td><p>Critical organ bleeding*</p></td><td><p>91</p><p>(0.82)</p></td><td><p>133 (1.18)</p></td><td colspan="2"><p>0.69 (0.53 - 0.91)</p><p>0.007</p></td></tr><tr><td><p>Intracranial haemorrhage*</p></td><td><p>55&nbsp;</p><p>(0.49)</p></td><td><p>84</p><p>(0.74)</p></td><td colspan="2"><p>0.67 (0.47 - 0.93)</p><p>0.019</p></td></tr><tr><td><p>Haemoglobin drop*</p></td><td><p>305 (2.77)</p></td><td><p>254 (2.26)</p></td><td colspan="2"><p>1.22 (1.03 - 1.44)</p><p>0.019</p></td></tr><tr><td><p>Transfusion of 2 or more units of packed red blood cells or whole blood*</p></td><td><p>183 (1.65)</p></td><td><p>149 (1.32)</p></td><td colspan="2"><p>1.25 (1.01 - 1.55)</p><p>0.044</p></td></tr><tr><td><p>Non-major &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; clinically</p><p>relevant bleeding events</p></td><td><p>1,185</p><p>(11.80)</p></td><td><p>1,151</p><p>(11.37)</p></td><td colspan="2"><p>1.04 (0.96 - 1.13)</p><p>0.345</p></td></tr><tr><td><p>All-cause mortality</p></td><td><p>208 (1.87)</p></td><td><p>250 (2.21)</p></td><td colspan="2"><p>0.85 (0.70 - 1.02)</p><p>0.073</p></td></tr><tr><td colspan="2"><p>a) Safety population, on treatment</p><p>* Nominally significant</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>In addition to the phase III ROCKET AF study, a prospective, single-arm, post-authorization, non-interventional, open-label cohort study (XANTUS) with central outcome adjudication including thromboembolic events and major bleeding has been conducted. 6,785 patients with non-valvular atrial fibrillation were enrolled for prevention of stroke and non-central nervous system (CNS) systemic embolism in clinical practice. The mean CHADS<sub>2</sub> and HAS-BLED scores were both 2.0 in XANTUS, compared to a mean CHADS<sub>2</sub> and HAS-BLED score of 3.5 and 2.8 in ROCKET AF, respectively. Major bleeding occurred in 2.1 per 100 patient years. Fatal haemorrhage was reported in 0.2 per 100 patient years and intracranial haemorrhage in 0.4 per 100 patient years. Stroke or non-CNS systemic embolism was recorded in 0.8 per 100 patient years.&nbsp;</p><p>These observations in clinical practice are consistent with the established safety profile in this indication.</p><p><u>Patients undergoing cardioversion&nbsp;</u></p><p>A prospective, randomised, open-label, multicentre, exploratory study with blinded endpoint evaluation (X-VERT) was conducted in 1504 patients (oral anticoagulant naive and pre-treated) with non-valvular atrial fibrillation scheduled for cardioversion to compare rivaroxaban with dose-adjusted VKA (randomised 2:1), for the prevention of cardiovascular events. TEE- guided (1 - 5 days of pre-treatment) or conventional cardioversion (at least three weeks of pre-treatment) strategies were employed. The primary efficacy outcome (all stroke, transient ischaemic attack, non-CNS systemic embolism, myocardial infarction (MI) and cardiovascular death) occurred in 5 (0.5%) patients in the rivaroxaban group (n = 978) and 5 (1.0%) patients in the VKA group (n = 492; RR 0.50; 95% CI 0.15-1.73; modified ITT population). The principal safety outcome (major bleeding) occurred in 6 (0.6%) and 4 (0.8%) patients in the rivaroxaban (n = 988) and VKA (n = 499) groups, respectively (RR 0.76; 95 % CI 0.21-2.67; safety population). This exploratory study showed comparable efficacy and safety between rivaroxaban and VKA treatment groups in the setting of cardioversion.</p><p>Patients with non-valvular atrial fibrillation who undergo PCI with stent placement&nbsp;</p><p>A randomised, open-label, multicentre study (PIONEER AF-PCI) was conducted in 2,124 patients with non-valvular atrial fibrillation who underwent PCI with stent placement for primary atherosclerotic disease to compare safety of two rivaroxaban regimens and one VKA regimen. Patients were randomly assigned in a 1:1:1 fashion for an overall 12-month-therapy. Patients with a history of stroke or TIA were excluded.&nbsp;</p><p>Group 1 received rivaroxaban 15 mg once daily (10 mg once daily in patients with creatinine clearance 30 - 49 ml/min) plus P2Y12 inhibitor. Group 2 received rivaroxaban 2.5 mg twice daily plus DAPT (dual antiplatelet therapy i.e. clopidogrel 75 mg [or alternate P2Y12 inhibitor] plus low-dose acetylsalicylic acid [ASA]) for 1, 6 or 12 months followed by rivaroxaban 15 mg (or 10 mg for subjects with creatinine clearance 30 - 49 ml/min) once daily plus low-dose ASA. Group 3 received dose-adjusted VKA plus DAPT for 1, 6 or 12 months followed by doseadjusted VKA plus low-dose ASA.&nbsp;</p><p>The primary safety endpoint, clinically significant bleeding events, occurred in 109 (15.7%), 117 (16.6%), and 167 (24.0%) subjects in group 1, group 2 and group 3, respectively (HR 0.59; 95% CI 0.47-0.76; p&lt;0.001, and HR 0.63; 95% CI 0.50-0.80; p&lt;0.001, respectively). The secondary endpoint (composite of cardiovascular events CV death, MI, or stroke) occurred in 41 (5.9%), 36 (5.1%), and 36 (5.2%) subjects in the group 1, group 2 and group 3, respectively. Each of the rivaroxaban regimens showed a significant reduction in clinically significant bleeding events compared to the VKA regimen in patients with non-valvular atrial fibrillation who underwent a PCI with stent placement.</p><p>The primary objective of PIONEER AF-PCI was to assess safety. Data on efficacy (including thromboembolic events) in this population are limited.</p><p>Treatment of DVT, PE and prevention of recurrent DVT and PE &nbsp;</p><p>The Xarelto clinical programme was designed to demonstrate the efficacy of Xarelto in the initial and continued treatment of acute DVT and PE and prevention of recurrence.</p><p>Over 12,800 patients were studied in four randomised controlled phase III clinical studies (Einstein DVT, Einstein PE, Einstein Extension and Einstein Choice) and additionally a predefined pooled analysis of the Einstein DVT and Einstein PE studies was conducted. The overall combined treatment duration in all studies was up to 21 months.</p><p>In Einstein DVT 3,449 patients with acute DVT were studied for the treatment of DVT and the prevention of recurrent DVT and PE (patients who presented with symptomatic PE were excluded from this study). The treatment duration was for 3, 6 or 12 months depending on the clinical judgement of the investigator.</p><p>For the initial 3 week treatment of acute DVT 15 mg rivaroxaban was administered twice daily. This was followed by 20 mg rivaroxaban once daily.&nbsp;</p><p>In Einstein PE, 4,832 patients with acute PE were studied for the treatment of PE and the prevention of recurrent DVT and PE. The treatment duration was for 3, 6 or 12 months depending on the clinical judgement of the investigator.</p><p>For the initial treatment of acute PE 15 mg rivaroxaban was administered twice daily for three weeks. This was followed by 20 mg rivaroxaban once daily.</p><p>In both the Einstein DVT and the Einstein PE study, the comparator treatment regimen consisted of enoxaparin administered for at least 5 days in combination with vitamin K antagonist treatment until the PT/INR was in therapeutic range (&ge; 2.0). Treatment was continued with a vitamin K antagonist dose-adjusted to maintain the PT/INR values within the therapeutic range of 2.0 to 3.0.</p><p>In Einstein Extension 1,197 patients with DVT or PE were studied for the prevention of recurrent DVT and PE. The treatment duration was for an additional 6 or 12 months in patients who had completed 6 to 12 months of treatment for venous thromboembolism depending on the clinical judgment of the investigator. Xarelto 20 mg once daily was compared with placebo.&nbsp;</p><p>Einstein DVT, PE and Extension used the same pre-defined primary and secondary efficacy outcomes. The primary efficacy outcome was symptomatic recurrent VTE defined as the composite of recurrent DVT or fatal or non-fatal PE. The secondary efficacy outcome was defined as the composite of recurrent DVT, non-fatal PE and all-cause mortality.&nbsp;</p><p>In Einstein Choice, 3,396 patients with confirmed symptomatic DVT and/or PE who completed 6-12 months of anticoagulant treatment were studied for the prevention of fatal PE or non-fatal symptomatic recurrent DVT or PE. Patients with an indication for continued therapeutic-dosed anticoagulation were excluded from the study. The treatment duration was up to 12 months depending on the individual randomisation date (median: 351 days). Xarelto 20 mg once daily and Xarelto 10 mg once daily were compared with 100 mg acetylsalicylic acid once daily.&nbsp;</p><p>The primary efficacy outcome was symptomatic recurrent VTE defined as the composite of recurrent DVT or fatal or non-fatal PE.&nbsp;</p><p>In the Einstein DVT study (see Table 6) rivaroxaban was demonstrated to be non-inferior to enoxaparin/VKA for the primary efficacy outcome (p &lt; 0.0001 (test for non-inferiority); HR: 0.680 (0.443 - 1.042), p=0.076 (test for superiority)). The prespecified net clinical benefit (primary efficacy outcome plus major bleeding events) was reported with a HR of 0.67 ((95% CI: 0.47 - 0.95), nominal p value p=0.027) in favour of rivaroxaban. INR values were within the therapeutic range a mean of 60.3% of the time for the mean treatment duration of 189 days, and 55.4%, 60.1%, and 62.8% of the time in the 3-, 6-, and 12-month intended treatment duration groups, respectively. In the enoxaparin/VKA group, there was no clear relation between the level of mean centre TTR (Time in Target INR Range of 2.0 - 3.0) in the equally sized tertiles and the incidence of the recurrent VTE (P=0.932 for interaction). Within the highest tertile according to centre, the HR with rivaroxaban versus warfarin was 0.69 (95% CI: 0.35 - 1.35).</p><p>The incidence rates for the primary safety outcome (major or clinically relevant non-major bleeding events) as well as the secondary safety outcome (major bleeding events) were similar for both treatment groups.</p><p><strong>Table 6: Efficacy and safety results from phase III Einstein DVT</strong>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Study population</strong>&nbsp;</p></td><td><p><strong>3,449 &nbsp; patients &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sym thrombosis</strong>&nbsp;</p></td><td><p><strong>ptomatic &nbsp;&nbsp; acute &nbsp;&nbsp; deep </strong></p></td><td><p><strong>vein</strong></p></td></tr><tr><td><p><strong>Treatment dose and duration</strong>&nbsp;</p></td><td><p><strong>Xarelto<sup>a)</sup></strong>&nbsp;</p><p><strong>3, 6 or 12 months</strong>&nbsp;</p><p><strong>N=1,731</strong>&nbsp;</p></td><td><p><strong>Enoxaparin/VKA<sup>b)</sup></strong>&nbsp;</p><p><strong>3, 6 or 12 months</strong>&nbsp;</p><p><strong>N=1,718</strong>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Symptomatic recurrent VTE*</p></td><td><p>36</p><p>(2.1%)</p></td><td><p>51</p><p>(3.0%)</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Symptomatic recurrent PE</p></td><td><p>20</p><p>(1.2%)</p></td><td><p>18</p><p>(1.0%)</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Symptomatic recurrent DVT</p></td><td><p>14</p><p>(0.8%)</p></td><td><p>28</p><p>(1.6%)</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Symptomatic PE and DVT</p></td><td><p>1 (0.1%)</p></td><td><p>0</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Fatal PE/death where PE cannot be ruled out</p></td><td><p>4 (0.2%)</p></td><td><p>6 (0.3%)</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Major or clinically relevant nonmajor bleeding</p></td><td><p>139</p><p>(8.1%)</p></td><td colspan="2"><p>138</p><p>(8.1%)</p></td></tr><tr><td><p>Major bleeding events</p></td><td><p>14</p><p>(0.8%)</p></td><td colspan="2"><p>20</p><p>(1.2%)</p></td></tr><tr><td colspan="4"><p>a)&nbsp;&nbsp; Rivaroxaban 15 mg twice daily for 3 weeks followed by 20 mg once daily</p><p>b)&nbsp; Enoxaparin for at least 5 days, overlapped with and followed by VKA</p><p><strong>*</strong> p &lt; 0.0001 (non-inferiority to a prespecified HR of 2.0); HR: 0.680 (0.443 - 1.042), p=0.076 (superiority)</p></td></tr></tbody></table><p>&nbsp;</p><p>In the Einstein PE study (see Table 7) rivaroxaban was demonstrated to be non-inferior to enoxaparin/VKA for the primary efficacy outcome (p=0.0026 (test for non-inferiority); HR: 1.123 (0.749 - 1.684)). The prespecified net clinical benefit (primary efficacy outcome plus major bleeding events) was reported with a HR of 0.849 ((95% CI: 0.633 - 1.139), nominal p value p= 0.275). INR values were within the therapeutic range a mean of 63% of the time for the mean treatment duration of 215 days, and 57%, 62%, and 65% of the time in the 3-, 6-, and 12month intended treatment duration groups, respectively. In the enoxaparin/VKA group, there was no clear relation between the level of mean centre TTR (Time in Target INR Range of 2.0 - 3.0) in the equally sized tertiles and the incidence of the recurrent VTE (p=0.082 for interaction). Within the highest tertile according to centre, the HR with rivaroxaban versus warfarin was</p><p>0.642 (95% CI: 0.277 - 1.484).</p><p>The incidence rates for the primary safety outcome (major or clinically relevant non-major bleeding events) were slightly lower in the rivaroxaban treatment group (10.3% (249/2412)) than in the enoxaparin/VKA treatment group (11.4% (274/2405)). The incidence of the secondary safety outcome (major bleeding events) was lower in the rivaroxaban group (1.1% (26/2412)) than in the enoxaparin/VKA group (2.2% (52/2405)) with a HR 0.493 (95% CI: 0.308 - 0.789).</p><p><strong>Table 7: Efficacy and safety results from phase III Einstein PE</strong>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Study population</strong>&nbsp;</p></td><td colspan="2"><p><strong>4,832 patients with an acute symptomatic PE</strong>&nbsp;</p></td></tr><tr><td><p><strong>Treatment dose and duration</strong>&nbsp;</p></td><td><p><strong>Xarelto<sup>a)</sup></strong>&nbsp;</p><p><strong>3, 6 or 12 months</strong>&nbsp;</p><p><strong>N=2,419</strong>&nbsp;</p></td><td><p><strong>Enoxaparin/VKA<sup>b)</sup></strong>&nbsp;</p><p><strong>3, 6 or 12 months</strong>&nbsp;</p><p><strong>N=2,413</strong>&nbsp;</p></td></tr><tr><td><p>Symptomatic recurrent VTE*</p></td><td><p>50</p><p>(2.1%)</p></td><td><p>44</p><p>(1.8%)</p></td></tr><tr><td><p>Symptomatic recurrent PE</p></td><td><p>23</p><p>(1.0%)</p></td><td><p>20</p><p>(0.8%)</p></td></tr><tr><td><p>Symptomatic recurrent DVT</p></td><td><p>18</p></td><td><p>17</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>(0.7%)</p></td><td><p>(0.7%)</p></td></tr><tr><td><p>Symptomatic PE and DVT</p></td><td><p>0</p></td><td><p>2 (&lt;0.1%)</p></td></tr><tr><td><p>Fatal PE/death where PE cannot be ruled out</p></td><td><p>11</p><p>(0.5%)</p></td><td><p>7 (0.3%)</p></td></tr><tr><td><p>Major or clinically relevant nonmajor bleeding</p></td><td><p>249</p><p>(10.3%)</p></td><td><p>274</p><p>(11.4%)</p></td></tr><tr><td><p>Major bleeding events</p></td><td><p>26</p><p>(1.1%)</p></td><td><p>52</p><p>(2.2%)</p></td></tr><tr><td colspan="3"><p>a)&nbsp;&nbsp; Rivaroxaban 15 mg twice daily for 3 weeks followed by 20 mg once daily</p><p>b)&nbsp; Enoxaparin for at least 5 days, overlapped with and followed by VKA</p><p>* p &lt; 0.0026 (non-inferiority to a prespecified HR of 2.0); HR: 1.123 (0.749 - 1.684)&nbsp;</p></td></tr></tbody></table><p>A prespecified pooled analysis of the outcome of the Einstein DVT and PE studies was conducted (see Table 8).</p><p><strong>Table 8: Efficacy and safety results from pooled analysis of phase III Einstein DVT and Einstein PE</strong>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Study population</strong>&nbsp;</p></td><td colspan="2"><p><strong>8,281 patients with an acute symptomatic DVT or PE</strong>&nbsp;</p></td></tr><tr><td><p><strong>Treatment dose and duration</strong>&nbsp;</p></td><td><p><strong>Xarelto<sup>a)</sup></strong>&nbsp;</p><p><strong>3, 6 or 12 months</strong>&nbsp;</p><p><strong>N=4,150</strong>&nbsp;</p></td><td><p><strong>Enoxaparin/VKA<sup>b)</sup></strong>&nbsp;</p><p><strong>3, 6 or 12 months</strong>&nbsp;</p><p><strong>N=4,131</strong>&nbsp;</p></td></tr><tr><td><p>Symptomatic recurrent VTE*</p></td><td><p>86</p><p>(2.1%)</p></td><td><p>95</p><p>(2.3%)</p></td></tr><tr><td><p>Symptomatic recurrent PE</p></td><td><p>43</p><p>(1.0%)</p></td><td><p>38</p><p>(0.9%)</p></td></tr><tr><td><p>Symptomatic recurrent DVT</p></td><td><p>32</p><p>(0.8%)</p></td><td><p>45</p><p>(1.1%)</p></td></tr><tr><td><p>Symptomatic PE and DVT</p></td><td><p>1 (&lt;0.1%)</p></td><td><p>2 (&lt;0.1%)</p></td></tr><tr><td><p>Fatal PE/death where PE cannot be ruled out</p></td><td><p>15</p><p>(0.4%)</p></td><td><p>13</p><p>(0.3%)</p></td></tr><tr><td><p>Major or clinically relevant nonmajor bleeding</p></td><td><p>388</p><p>(9.4%)</p></td><td><p>412</p><p>(10.0%)</p></td></tr><tr><td><p>Major bleeding events</p></td><td><p>40</p><p>(1.0%)</p></td><td><p>72</p><p>(1.7%)</p></td></tr></tbody></table><p>a)&nbsp;&nbsp; Rivaroxaban 15 mg twice daily for 3 weeks followed by 20 mg once daily</p><p>b)&nbsp; Enoxaparin for at least 5 days, overlapped with and followed by VKA</p><p><strong>*</strong> p &lt; 0.0001 (non-inferiority to a prespecified HR of 1.75); HR: 0.886 (0.661 - 1.186)</p><p>&nbsp;</p><p>The prespecified net clinical benefit (primary efficacy outcome plus major bleeding events) of the pooled analysis was reported with a HR of 0.771 ((95% CI: 0.614 - 0.967), nominal p value p = 0.0244).</p><p>In the Einstein Extension study (see Table 9) rivaroxaban was superior to placebo for the primary and secondary efficacy outcomes. For the primary safety outcome (major bleeding events) there was a non-significant numerically higher incidence rate for patients treated with rivaroxaban 20 mg once daily compared to placebo. The secondary safety outcome (major or clinically relevant non-major bleeding events) showed higher rates for patients treated with rivaroxaban 20 mg once daily compared to placebo.&nbsp;</p><p><strong>Table 9: Efficacy and safety results from phase III Einstein Extension</strong>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Study population</strong>&nbsp;</p></td><td colspan="2"><p><strong>1,197 patients continued treatment and prevention of recurrent venous thromboembolism</strong>&nbsp;</p></td></tr><tr><td><p><strong>Treatment dose and duration</strong>&nbsp;</p></td><td><p><strong>Xarelto<sup>a)</sup> </strong>&nbsp;</p><p><strong>6 or 12 months</strong>&nbsp;</p><p><strong>N=602</strong>&nbsp;</p></td><td><p><strong>Placebo</strong></p><p><strong>6 or 12 months</strong>&nbsp;</p><p><strong>N=594</strong>&nbsp;</p></td></tr><tr><td><p>Symptomatic recurrent VTE*</p></td><td><p>8 (1.3%)</p></td><td><p>42</p><p>(7.1%)</p></td></tr><tr><td><p>Symptomatic recurrent PE</p></td><td><p>2 (0.3%)</p></td><td><p>13</p><p>(2.2%)</p></td></tr><tr><td><p>Symptomatic recurrent DVT</p></td><td><p>5 (0.8%)</p></td><td><p>31</p><p>(5.2%)</p></td></tr><tr><td><p>Fatal PE/death where PE cannot be ruled out</p></td><td><p>1 (0.2%)</p></td><td><p>1 (0.2%)</p></td></tr><tr><td><p>Major bleeding events</p></td><td><p>4 (0.7%)</p></td><td><p>0 (0.0%)</p></td></tr><tr><td><p>Clinically &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; relevant &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; non-major bleeding</p></td><td><p>&nbsp;32 (5.4%)</p></td><td><p>7 (1.2%)</p></td></tr><tr><td colspan="3"><p>a) Rivaroxaban 20 mg once daily</p><p><strong>*</strong> p &lt; 0.0001 (superiority), HR: 0.185 (0.087 - 0.393)</p></td></tr></tbody></table><p>&nbsp;</p><p>In the Einstein Choice study (see Table 10) Xarelto 20 mg and 10 mg were both superior to 100 mg acetylsalicylic acid for the primary efficacy outcome. The principal safety outcome (major bleeding events) was similar for patients treated with Xarelto 20 mg and 10 mg once daily compared to 100 mg acetylsalicylic acid.&nbsp;</p><p>&nbsp;</p><p><strong>Table 10: Efficacy and safety results from phase III Einstein Choice </strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Study population</strong>&nbsp;</p></td><td colspan="3"><p><strong>3,396 patients continued prevention of recurrent venous thromboembolism</strong>&nbsp;</p></td></tr><tr><td><p><strong>Treatment dose </strong>&nbsp;</p></td><td><p><strong>Xarelto 20 mg od</strong>&nbsp;</p><p><strong>N=1,107</strong>&nbsp;</p></td><td><p><strong>Xarelto 10 mg od</strong>&nbsp;</p><p><strong>N=1,127</strong>&nbsp;</p></td><td><p><strong>ASA 100 mg od</strong>&nbsp;</p><p><strong>N=1,131</strong>&nbsp;</p></td></tr><tr><td><p>Treatment duration median</p><p>[interquartile range]</p></td><td><p>349 [189-362] days</p></td><td><p>353 [190-362] days</p></td><td><p>350 [186-362] days</p></td></tr><tr><td><p>Symptomatic recurrent VTE</p></td><td><p>17</p><p>(1.5%)*</p></td><td><p>13</p><p>(1.2%)**</p></td><td><p>50</p><p>(4.4%)</p></td></tr><tr><td><p>Symptomatic recurrent PE</p></td><td><p>6 (0.5%)</p></td><td><p>6 (0.5%)</p></td><td><p>19</p><p>(1.7%)</p></td></tr><tr><td><p>Symptomatic recurrent DVT</p></td><td><p>9 (0.8%)</p></td><td><p>8 (0.7%)</p></td><td><p>30</p><p>(2.7%)</p></td></tr><tr><td><p>Fatal PE/death where PE cannot be ruled out</p></td><td><p>2 (0.2%)</p></td><td><p>0 (0.0%)</p></td><td><p>2 (0.2%)</p></td></tr><tr><td><p>Symptomatic &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; recurrent</p><p>VTE, MI, stroke, or non-</p><p>CNS systemic embolism</p></td><td><p>19</p><p>(1.7%)</p></td><td><p>18</p><p>(1.6%)</p></td><td><p>56</p><p>(5.0%)</p></td></tr><tr><td><p>Major bleeding events</p></td><td><p>6 (0.5%)</p></td><td><p>5 (0.4%)</p></td><td><p>3 (0.3%)</p></td></tr><tr><td><p>Clinically relevant nonmajor bleeding</p></td><td><p>30&nbsp;</p><p>(2.7)</p></td><td><p>22&nbsp;</p><p>(2.0)</p></td><td><p>20&nbsp;</p><p>(1.8)</p></td></tr><tr><td><p>Symptomatic recurrent VTE or major bleeding (net</p><p>clinical benefit)</p></td><td><p>23&nbsp; (2.1%)<sup>+</sup></p></td><td><p>17&nbsp;</p><p>(1.5%)<sup>++</sup></p></td><td><p>53&nbsp; (4.7%)</p></td></tr><tr><td colspan="4"><p>* p&lt;0.001(superiority) Xarelto 20 mg od vs ASA 100 mg od; HR=0.34 (0.20-0.59)</p></td></tr></tbody></table><p>** p&lt;0.001 (superiority) Xarelto 10 mg od vs ASA 100 mg od; HR=0.26 (0.14-0.47)</p><p><sup>+ </sup>Xarelto 20 mg od vs. ASA 100 mg od; HR=0.44 (0.27-0.71), p=0.0009 (nominal)&nbsp;</p><p><sup>++</sup> Xarelto 10 mg od vs. ASA 100 mg od; HR=0.32 (0.18-0.55), p&lt;0.0001 (nominal)</p><p>&nbsp;</p><p>In addition to the phase III EINSTEIN programme, a prospective, non-interventional, open-label cohort study (XALIA) with central outcome adjudication including recurrent VTE, major bleeding and death has been conducted. 5,142 patients with acute DVT were enrolled to investigate the long-term safety of rivaroxaban compared with standard-of-care anticoagulation therapy in clinical practice. Rates of major bleeding, recurrent VTE and all-cause mortality for rivaroxaban were 0.7%, 1.4% and 0.5%, respectively. There were differences in patient baseline characteristics including age, cancer and renal impairment. A pre-specified propensity score stratified analysis was used to adjust for measured baseline differences but residual confounding may, in spite of this, influence the results. Adjusted HRs comparing rivaroxaban and standard-ofcare for major bleeding, recurrent VTE and all-cause mortality were 0.77 (95% CI 0.40 - 1.50),</p><p>0.91 (95% CI 0.54 - 1.54) and 0.51 (95% CI 0.24 - 1.07), respectively.&nbsp;</p><p>These results in clinical practice are consistent with the established safety profile in this indication.</p><p><u>Patients with high risk triple positive antiphospholipid syndrome&nbsp;</u></p><p>In an investigator sponsored, randomized open-label multicenter study with blinded endpoint adjudication, rivaroxaban was compared to warfarin in patients with a history of thrombosis, diagnosed with antiphospholipid syndrome and at high risk for thromboembolic events (positive for all 3 antiphospholipid tests: lupus anticoagulant, anticardiolipin antibodies, and anti-beta 2glycoprotein I antibodies). The trial was terminated prematurely after the enrolment of 120 patients due to an excess of events among patients in the rivaroxaban arm. Mean follow-up was 569 days. 59 patients were randomized to rivaroxaban 20 mg (15 mg for patients with creatinine clearance (CrCl) &lt;50 mL/min) and 61 to warfarin (INR 2.0-3.0). Thromboembolic events occurred in 12% of patients randomized to rivaroxaban (4 ischaemic strokes and 3 myocardial infarctions). No events were reported in patients randomized to warfarin. Major bleeding occurred in 4 patients (7%) of the rivaroxaban group and 2 patients (3%) of the warfarin group.</p><p><u>Paediatric population&nbsp;</u></p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with Xarelto in one or more subsets of the paediatric population in the treatment of thromboembolic events. The European Medicines Agency has waived the obligation to submit the results of studies with Xarelto in all subsets of the paediatric population in the prevention of thromboembolic events (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption&nbsp;</u></p><p>Rivaroxaban is rapidly absorbed with maximum concentrations (C<sub>max</sub>) appearing 2 - 4 hours after tablet intake.&nbsp;</p><p>Oral absorption of rivaroxaban is almost complete and oral bioavailability is high (80 - 100%) for the 2.5 mg and 10 mg tablet dose, irrespective of fasting/fed conditions. Intake with food does not affect rivaroxaban AUC or C<sub>max</sub> at the 2.5 mg and 10 mg dose.&nbsp;</p><p>Due to a reduced extent of absorption an oral bioavailability of 66% was determined for the 20 mg tablet under fasting conditions. When Xarelto 20 mg tablets are taken together with food increases in mean AUC by 39% were observed when compared to tablet intake under fasting conditions, indicating almost complete absorption and high oral bioavailability. Xarelto 15 mg and 20 mg are to be taken with food (see section 4.2).</p><p>Rivaroxaban pharmacokinetics are approximately linear up to about 15 mg once daily in fasting state. Under fed conditions Xarelto 10 mg, 15 mg and 20 mg tablets demonstrated doseproportionality. At higher doses rivaroxaban displays dissolution limited absorption with decreased bioavailability and decreased absorption rate with increased dose.&nbsp;</p><p>Variability in rivaroxaban pharmacokinetics is moderate with inter-individual variability (CV%) ranging from 30% to 40%.</p><p>Absorption of rivaroxaban is dependent on the site of its release in the gastrointestinal tract. A 29% and 56% decrease in AUC and C<sub>max</sub> compared to tablet was reported when rivaroxaban granulate is released in the proximal small intestine. Exposure is further reduced when rivaroxaban is released in the distal small intestine, or ascending colon. Therefore, administration of rivaroxaban distal to the stomach should be avoided since this can result in reduced absorption and related rivaroxaban exposure.</p><p>Bioavailability (AUC and C<sub>max</sub>) was comparable for 20 mg rivaroxaban administered orally as a crushed tablet mixed in apple puree, or suspended in water and administered via a gastric tube followed by a liquid meal, compared to a whole tablet. Given the predictable, dose-proportional pharmacokinetic profile of rivaroxaban, the bioavailability results from this study are likely applicable to lower rivaroxaban doses.</p><p><u>Distribution&nbsp;</u></p><p>Plasma protein binding in humans is high at approximately 92% to 95%, with serum albumin being the main binding component. The volume of distribution is moderate with V<sub>ss</sub> being approximately 50 litres.</p><p><u>Biotransformation and elimination&nbsp;</u></p><p>Of the administered rivaroxaban dose, approximately 2/3 undergoes metabolic degradation, with half then being eliminated renally and the other half eliminated by the faecal route. The final 1/3 of the administered dose undergoes direct renal excretion as unchanged active substance in the urine, mainly via active renal secretion.</p><p>Rivaroxaban is metabolised via CYP3A4, CYP2J2 and CYP-independent mechanisms. Oxidative degradation of the morpholinone moiety and hydrolysis of the amide bonds are the major sites of biotransformation. Based on <em>in vitro</em> investigations rivaroxaban is a substrate of the transporter proteins P-gp (P-glycoprotein) and Bcrp (breast cancer resistance protein).</p><p>Unchanged rivaroxaban is the most important compound in human plasma, with no major or active circulating metabolites being present. With a systemic clearance of about 10 l/h, rivaroxaban can be classified as a low-clearance substance. After intravenous administration of a 1 mg dose the elimination half-life is about 4.5 hours. After oral administration the elimination becomes absorption rate limited. Elimination of rivaroxaban from plasma occurs with terminal half-lives of 5 to 9 hours in young individuals, and with terminal half-lives of 11 to 13 hours in the elderly.</p><p><u>Special populations&nbsp;</u></p><p>Gender&nbsp;</p><p>There were no clinically relevant differences in pharmacokinetics and pharmacodynamics between male and female patients.</p><p>Elderly population&nbsp;</p><p>Elderly patients exhibited higher plasma concentrations than younger patients, with mean AUC values being approximately 1.5 fold higher, mainly due to reduced (apparent) total and renal clearance. No dose adjustment is necessary.</p><p>Different weight categories&nbsp;</p><p>Extremes in body weight (&lt; 50 kg or &gt; 120 kg) had only a small influence on rivaroxaban plasma concentrations (less than 25%). No dose adjustment is necessary.</p><p>Inter-ethnic differences&nbsp;</p><p>No clinically relevant inter-ethnic differences among Caucasian, African-American, Hispanic, Japanese or Chinese patients were observed regarding rivaroxaban pharmacokinetics and pharmacodynamics.</p><p>Hepatic impairment&nbsp;</p><p>Cirrhotic patients with mild hepatic impairment (classified as Child Pugh A) exhibited only minor changes in rivaroxaban pharmacokinetics (1.2 fold increase in rivaroxaban AUC on average), nearly comparable to their matched healthy control group. In cirrhotic patients with moderate hepatic impairment (classified as Child Pugh B), rivaroxaban mean AUC was significantly increased by 2.3 fold compared to healthy volunteers. Unbound AUC was increased 2.6 fold. These patients also had reduced renal elimination of rivaroxaban, similar to patients with moderate renal impairment. There are no data in patients with severe hepatic impairment.</p><p>The inhibition of factor Xa activity was increased by a factor of 2.6 in patients with moderate hepatic impairment as compared to healthy volunteers; prolongation of PT was similarly increased by a factor of 2.1. Patients with moderate hepatic impairment were more sensitive to rivaroxaban resulting in a steeper PK/PD relationship between concentration and PT.&nbsp;</p><p>Xarelto is contraindicated in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk, including cirrhotic patients with Child Pugh B and C (see section 4.3).</p><p>Renal impairment&nbsp;</p><p>There was an increase in rivaroxaban exposure correlated to decrease in renal function, as assessed via creatinine clearance measurements. In individuals with mild (creatinine clearance 50 - 80 ml/min), moderate (creatinine clearance 30 - 49 ml/min) and severe (creatinine clearance 15 - 29 ml/min) renal impairment, rivaroxaban plasma concentrations (AUC) were increased 1.4, 1.5 and 1.6 fold respectively. Corresponding increases in pharmacodynamic effects were more pronounced. In individuals with mild, moderate and severe renal impairment the overall inhibition of factor Xa activity was increased by a factor of 1.5, 1.9 and 2.0 respectively as compared to healthy volunteers; prolongation of PT was similarly increased by a factor of 1.3,</p><p>2.2 and 2.4 respectively. There are no data in patients with creatinine clearance &lt; 15 ml/min.</p><p>Due to the high plasma protein binding rivaroxaban is not expected to be dialysable.</p><p>Use is not recommended in patients with creatinine clearance &lt; 15 ml/min. Xarelto is to be used with caution in patients with creatinine clearance 15 - 29 ml/min (see section 4.4).</p><p><u>Pharmacokinetic data in patients&nbsp;</u></p><p>In patients receiving rivaroxaban for treatment of acute DVT 20 mg once daily the geometric mean concentration (90% prediction interval) 2 - 4 h and about 24 h after dose (roughly representing maximum and minimum concentrations during the dose interval) was 215 (22 - 535) and 32 (6 - 239) mcg/l, respectively.</p><p><u>Pharmacokinetic/pharmacodynamic relationship&nbsp;</u></p><p>The pharmacokinetic/pharmacodynamic (PK/PD) relationship between rivaroxaban plasma concentration and several PD endpoints (factor Xa inhibition, PT, aPTT, Heptest) has been evaluated after administration of a wide range of doses (5 - 30 mg twice a day). The relationship between rivaroxaban concentration and factor Xa activity was best described by an E<sub>max</sub> model. For PT, the linear intercept model generally described the data better. Depending on the different PT reagents used, the slope differed considerably. When Neoplastin PT was used, baseline PT was about 13 s and the slope was around 3 to 4 s/(100 mcg/l). The results of the PK/PD analyses in Phase II and III were consistent with the data established in healthy subjects.&nbsp;</p><p><u>Paediatric population&nbsp;</u></p><p>Safety and efficacy have not been established for children and adolescents up to 18 years.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, single dose toxicity, phototoxicity, genotoxicity, carcinogenic potential and juvenile toxicity.</p><p>Effects observed in repeat-dose toxicity studies were mainly due to the exaggerated pharmacodynamic activity of rivaroxaban. In rats, increased IgG and IgA plasma levels were seen at clinically relevant exposure levels.</p><p>In rats, no effects on male or female fertility were seen. Animal studies have shown reproductive toxicity related to the pharmacological mode of action of rivaroxaban (e.g. haemorrhagic complications). Embryo-foetal toxicity (post-implantation loss, retarded/progressed ossification, hepatic multiple light coloured spots) and an increased incidence of common malformations as well as placental changes were observed at clinically relevant plasma concentrations. In the pre- and post-natal study in rats, reduced viability of the offspring was observed at doses that were toxic to the dams.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Rivax (Rivaroxaban 2.5 mg):</u> </strong></p><p>Each film coated tablet contains Rivaroxaban 2.5mg.</p><p><strong>The other ingredients are:</strong> Cellulose, microcrystalline (Grade 101), Lactose monohydrate</p><p>(Grade 200M), Croscarmellose sodium, Hypromellose 2910,5cps, Sodiumlauril sulfate, Magnesium stearate, Purified water, Opadry white, Opadry 04F530020 Orange, Opadry 04F57002 Grey and Opadry 04F57000 Grey&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 Years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>below 30&ordm;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Blister pack</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Saudi Hetero Lab Ltd.
Al-jameah Street, Malaz quarter,
Riyadh 11441, Saudi Arabia.  
Tel: +966 11 477 2215  
Manufacture:  
Hetero Lab Limited Unit V, Hyderabad, India. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                NA
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>